










































Drug discovery for remyelination and treatment of MS
Citation for published version:
Cole, KLH, Early, JJ & Lyons, DA 2017, 'Drug discovery for remyelination and treatment of MS' Glia. DOI:
10.1002/glia.23166
Digital Object Identifier (DOI):
10.1002/glia.23166
Link:






Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
	   1	  
Drug  discovery  for  remyelination  and  treatment  of  MS  
  
Running  title:  Drug  discovery  for  remyelination  
  
  
Katy  LH  Cole1,  Jason  J  Early1,  and  David  A  Lyons1.  
  
  
1:   Centre   for   Neuroregeneration,   MS   Society   Centre   for   Translational   Research,   Euan  
MacDonald   Centre   for   Motor   Neurone   Disease   Research,   University   of   Edinburgh,  
Edinburgh  EH16  4SB,  UK.  
  
Correspondence  to    
Katy  LH  Cole:  kcole2@exseed.ed.ac.uk    
Jason  J  Early:  Jason.early@ed.ac.uk  
David  A  Lyons:  david.lyons@ed.ac.uk  
  
Main  points:  
Enhancing  remyelination  is  a  potential  treatment  for  MS  
Recent   studies   have   identified   numerous   compounds   that   promote  
remyelination  
New  technologies  will  further  accelerate  MS  drug  discovery  
  
  
	   2	  
  
Abstract    
Glia  constitute  the  majority  of  the  cells  in  our  nervous  system,  yet  there  are  currently  
no  drugs  that   target  glia   for   the  treatment  of  disease.  Given  ongoing  discoveries  of  
the  many  roles  of  glia   in  numerous  diseases  of  the  nervous  system,  this   is   likely  to  
change   in   years   to   come.   Here   we   focus   on   the   possibility   that   targeting   the  
oligodendrocyte   lineage   to   promote   regeneration   of   myelin   (remyelination)  
represents   a   therapeutic   strategy   for   the   treatment   of   the   demyelinating   disease  
multiple   sclerosis,   MS.  We   discuss   how   hypothesis   driven   studies   have   identified  
multiple   targets  and  pathways  that  can  be  manipulated  to  promote  remyelination   in  
vivo,  and  how  this  work  has  led  to  the  first  ever  remyelination  clinical  trials.  We  also  
highlight   how   recent   chemical   discovery   screens   have   identified   a   host   of   small  
molecule  compounds   that  promote  oligodendrocyte  differentiation   in  vitro.  Some  of  
these   compounds   have   also   been   shown   to   promote  myelin   regeneration   in   vivo,  
with  one  already  being  trialled  in  humans.  Promoting  oligodendrocyte  differentiation  
and  remyelination  represents  just  one  potential  strategy  for  the  treatment  of  MS.  The  
pathology   of   MS   is   complex,   and   its   complete   amelioration   may   require   targeting  
multiple  biological  processes   in  parallel.  Therefore,  we  present  an  overview  of  new  
technologies   and   models   for   phenotypic   analyses   and   screening   that   can   be  
exploited  to  study  complex  cell-­cell  interactions  in  in  vitro  and  in  vivo  systems.  Such  
technological   platforms   will   provide   insight   into   fundamental   mechanisms   and  
increase  capacities   for  drug-­discovery  of   relevance   to  glia  and  currently   intractable  
disorders  of  the  CNS.  
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Introduction  
Glia   represent   the  majority   of   cells   in   our   nervous   system.   Although   long-­cited   to  
represent  90%  of  the  cells  in  the  human  central  nervous  system  (CNS),  more  recent  
estimates   suggest   that   this   may   closer   to   half   (Bartheld,   Bahney,   &   Herculano-­
Houzel,  2016).  Whatever  the  numerical  contribution  of  glia  cells  may  be,  advances  in  
recent  years  have  firmly  established  the  fundamental  roles  of  glial  cells  in  regulating  
many  aspects  of  nervous  system  formation,  function,  and  dysfunction.  The  myriad  of  
essential   functions   of   oligodendrocyte   progenitor   cells   (OPCs),   oligodendrocytes,  
astrocytes   and   microglia   in   the   CNS   have   been   extensively   reviewed   elsewhere  
(Chung,   Welsh,   Barres,   &   Stevens,   2015;;   Freeman   &   Rowitch,   2013;;   Zuchero   &  
Barres,   2015).   Highlighting   the   increasing   awareness   of   glial   cells   as   viable  
therapeutic   targets   for   the   treatment   of   disease,   Glia   recently   published   a   special  
issue  called  “Gliotherapeutics”  (Möller  &  Boddeke,  2016a).  In  that  issue  Moeller  and  
Boddeke  provided  an  overview  of  the  early  stages  of  drug  discovery  projects,  with  a  
focus   on   molecular   target-­driven   approaches   most   commonly   employed   in   the  
pharmaceutical   industry  (Möller  &  Boddeke,  2016b).  Additional  articles  focussed  on  
specific  molecular  targets  and  their  relationship  to  glia  for  disease  intervention  (Dale,  
Staal,  Eder,  &  Möller,  2016;;  Garden  &  Campbell,  2016;;  Möller  et  al.,  2016;;  Pearse  &  
Hughes,   2016),   and  on  emerging  evidence   that  microglial   play   a  major   role   in   the  
pathogenesis  of  Alzheimer’s  disease  (Wes,  Sayed,  Bard,  &  Gan,  2016).  Here  we  will  
focus   on   the   concept   that   enhancement   of   the   endogenous   process   of   myelin  
regeneration  (remyelination)  represents  a  promising  intervention  for  the  treatment  of  
multiple   sclerosis   (MS).   Indeed,   it   is   entirely   possible   that   remyelination-­enhancing  
medicines  will   come   to   represent   the   first   class   of   drugs   developed   specifically   to  
target  glia,  and  the  first   to  promote  bona  fide  regeneration  in  the  CNS.  We  will   first  
focus  on  how  hypothesis-­driven  studies  have  provided  candidate  pathways  that  can  
be   manipulated   to   promote   remyelination   in   vivo.   We   will   then   discuss   recent  
hypothesis-­generating   phenotypic   screens   of   small   molecule   compounds   that  
identified   novel   regulators   of   oligodendrocyte   biology   and   new   entry-­points   for   the  
enhancement  of  myelin  regeneration.  However,  the  pathology  of  MS  is  complex,  and  
effective   interventions   may   involve   targeting   multiple   cell   types   and   cell-­cell  
interactions,  and  possibly  doing  so  differentially  over  disease-­course.    Therefore,  it  is  
clear   that   integrated   analyses   of   the   role   of   distinct   cell   types   and   cell-­cell  
interactions  at  the  tissue,  organ  and  whole  animal  level  will  be  essential  for  gaining  a  
fuller  understanding  of   therapeutic  options.  As  such,   in   the  third  part  of   this  review,  
we   take   the  opportunity   to   focus  on  emerging   technologies   that  are  not   yet  widely  
employed   by   glial   cell   biologists,   but   which   are   sure   to   augment   both   hypothesis-­
driven  and  translational/  drug  discovery  research  in  general.  
Targeting  the  oligodendrocyte  lineage  for  the  treatment  of  disease  
The   fact   that  CNS  myelin   is   disrupted   in  MS  has  been   known   for   over   150   years,  
since   the   initial   identification   of   the   disease   by   Jean-­Martin   Charcot.   However,   in  
recent  years  it  has  become  clear  that  oligodendrocytes  (the  myelin-­producing  cells  of  
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the   CNS)   are   affected   in   numerous   neurodegenerative,   neurodevelopmental   and  
neuropsychiatric   disorders.   This   includes   disruption   to   oligodendrocytes   and  
myelinated  axons  in  Alzheimer’s  disease  (Bartzokis,  2011),  Huntington’s  disease  (B.  
Huang   et   al.,   2015),  Motor  Neuron   disease   (Kang   et   al.,   2013),   Downs   syndrome  
(Olmos-­Serrano  et  al.,  2016),  Autism  (Pacey  et  al.,  2013),  neonatal  hypoxia  (Buser  
et  al.,  2012),  and  schizophrenia  (Hercher,  Chopra,  &  Beasley,  2014),   in  addition   to  
numerous   leukodystrophies   characterised   by   widespread   disruption   to   the   white  
matter   (Boespflug-­Tanguy,   Labauge,   Fogli,   &   Vaurs-­Barriere,   2008).   Extensive  
fundamental   research  will  be   required   to  determine   to  what  extent  oligodendrocyte  
dysfunction   plays   primary   or   secondary   roles   in   different   conditions,   and   in   which  
diseases  targeting  of  the  oligodendrocyte  lineage  may  be  rational.  Therefore,  for  the  
purposes   of   this   review,   we   will   focus   on   the   now   rationale   that   enhancing   the  
endogenous  capacity  of  the  CNS  to  regenerate  myelin  represents  a  viable  option  for  
disease  intervention  in  MS.  
The  CNS  exhibits  an  impressive  endogenous  capacity  to  regenerate  myelin  following  
its  loss  (demyelination).  Remyelination  has  in  fact,  long  been  known  to  occur  in  MS  
(Prineas  &  Connell,   1979),   and   is   also   observed   following   numerous   experimental  
modes  of  demyelination  (e.g.  (Blakemore,  1974;;  M.  B.  Bunge,  Bunge,  &  RIS,  1961;;  
Gledhill,  Harrison,  &  McDonald,  1973;;  Reier  &  Webster,  1974))  and  oligodendrocyte  
ablation   (Gritsch  et   al.,   2014;;  Locatelli   et   al.,   2012;;  Pohl   et   al.,   2011;;  Traka  et   al.,  
2010).   The   regeneration   of   CNS   myelin   is   possible   because   of   the   existence   of  
oligodendrocyte  progenitor  cells  (OPCs,  also  called  oligodendrocyte  precursor  cells  
or   NG2   cells)   that   are   distributed   throughout   the   CNS   (Dawson,   Polito,   Levine,   &  
Reynolds,   2003).   OPCs   are   capable   of   generating   mature   myelin-­producing  
oligodendrocytes  from  early  development  well  into  adulthood  in  the  healthy  nervous  
system  (E.  G.  Hughes,  Kang,  Fukaya,  &  Bergles,  2013a;;  Yeung  et  al.,  2014;;  Young  
et   al.,   2013).   In   adults,   new   oligodendrocytes   can   be   generated   in   response   to  
learning   (McKenzie   et   al.,   2014;;   L.   Xiao   et   al.,   2016)   and,   importantly,   also   in  
response   to   demyelination   (Tripathi,   Rivers,   Young,   Jamen,   &   Richardson,   2010;;  
Zawadzka   et   al.,   2010).   However,   the   regenerative   process   of   remyelination   is  
imperfect,   declines   in   efficiency   with   age   (Goldschmidt,   Antel,   König,   Bruck,   &  
Kuhlmann,  2009;;  Ruckh  et  al.,  2012),  and  occurs   to  very  varying  degrees  between  
lesions   within   individual   MS   patients   and   between   different   individuals   (Hickey,  
1999).   Despite   the   complex   pathologies   of   MS,   the   presence   of   OPCs   with   an  
impaired   ability   to   differentiate   into   myelinating   oligodendrocytes   characterises   a  
large   proportion   of   MS   lesions   (A.   Chang,   Tourtellotte,   Rudick,   &   Trapp,   2002;;  
Kuhlmann  et  al.,  2008;;  Lucchinetti  et  al.,  1999;;  Ozawa  et  al.,  1994;;  Wolswijk,  1998).  
Therefore,   it   is   thought   that   interventions   intended   to   overcome   this   bottleneck   of  
oligodendrocyte   differentiation   may   enhance   myelin   regeneration.   But   why   might  
enhancing  remyelination  actually  impact  MS?  
Multiple   sclerosis   is   generally   thought   to   be   triggered   by   autoimmune-­mediated  
attack  of  CNS  myelin  (Compston  &  Coles,  2008).  Reflecting  the  inflammatory  trigger  
of   disease   is   the   fact   that   essentially   all   currently-­available   frontline   treatments   for  
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MS  target   the  adaptive   immune  system.  Such   treatments  are  now  very  effective   in  
reducing  the  number  and  severity  of  debilitating  immune-­mediated  attacks  during  the  
early   relapsing-­remitting   stages   of   disease   (Comi,  Radaelli,   &  Soelberg  Sørensen,  
2016).   However,   these   anti-­inflammatory   treatments   have   not   yet   been   shown  
capable  of  preventing  progression  of  disease  beyond  the  relapsing-­remitting  stage  to  
the   later   progressive   stage  of   disease,  which   is   characterised  by  extensive  axonal  
degeneration  (Trapp  et  al.,  1998).  There  are  currently  no  treatments  available  for  the  
progressive  stages  of  disease,  which  represents  a  huge  unmet  challenge.  It   is  now  
thought   that   long-­term   demyelination   contributes   to   the   emergence   of  
neurodegeneration   seen   in   progressive   stages   of   MS.   Demyelination  may   lead   to  
axonal   and   neuronal   degeneration   in   multiple   ways.   First,   demyelination   leaves  
axons   exposed   to   potentially   damaging   signals   in   the  microenvironment,   including  
those  released  by  cells  of   the   innate   immune  system  (Mahad,  Trapp,  &  Lassmann,  
2015).  Demyelination  also  leads  to  dysregulation  of  conduction  (McDonald  &  Sears,  
1969),   and   to   the   insertion   of   ion   channels   and   transporters   into   the   axonal  
membrane   to  maintain  activity   (Craner,  Lo,  Black,  &  Waxman,  2003;;  Craner  et  al.,  
2004;;   Prineas  &  Connell,   1979):   such   adaptations  may   inadvertently   lead   to   large  
influxes  of  ions,  such  as  the  import  of  excessive  and  damaging  amounts  of  Ca2+  into  
the   axon   (Franklin,   Ffrench-­Constant,   Edgar,   &   Smith,   2012;;   Lassmann,   van  
Horssen,  &  Mahad,  2012;;  Waxman,  2006).   In  addition,  myelin  provides  trophic  and  
metabolic   support   to  axons   (Fünfschilling  et  al.,   2012;;  Nave  &  Trapp,  2008;;  Saab,  
Tzvetanova,  &  Nave,  2013),   the  disruption  of  which  can   in  principle   lead   to  axonal  
degeneration   (Y.   Lee   et   al.,   2012b),   and   possibly   also   in   MS.   Such   key   roles   of  
myelin  in  maintaining  axonal  health  and  function  has  led  to  the  simple  concept  that  
promoting   myelin   regeneration   in   MS   may   not   only   help   restore   optimal   circuit  
function,  but  also  serve  to  protect  axons  and  neurons  from  degeneration  (Franklin  et  
al.,   2012).   Indeed,   experimental   studies   have   validated   the   premise   that  
remyelination  helps  restore  conduction  (K.  J.  Smith,  Blakemore,  &  McDonald,  1979),  
and   is   neuroprotective   (Irvine   &   Blakemore,   2008;;   Mei,   Lehmann-­Horn,   et   al.,  
2016a).   Therefore,   promotion   of   remyelination   is   considered   as   a   promising  
therapeutic  strategy  for  the  treatment  of  MS  (Franklin  &  Goldman,  2015).  However,  it  
is   important   to   note   that   the   pathology   of   MS   is   complex,   and   that   promotion   of  
remyelination  is  only  one  possible  strategy  for  intervention,  which  we  discuss  below.  
Hypothesis   driven   approaches   and   identification   of   strategies   to   promote  
myelin  regeneration  
In   recent   years,   our   understanding   of   the   molecular   mechanisms   governing  
oligodendrocyte   differentiation   and   myelination   has   increased   dramatically,   and   is  
summarised   in   numerous   reviews   (Ackerman  &  Monk,   2015;;  Baraban,  Mensch,   &  
Lyons,  2016;;  Bercury  &  Macklin,  2015;;  Emery  &  Lu,  2015;;  Gaesser  &  Fyffe-­Maricich,  
2016;;  Galloway  &  Moore,  2016;;  Nave  &  Werner,  2014).   Interestingly,  although   the  
contexts  of  developmental  myelination  and  myelin  regeneration  are  distinct,  there  is  
remarkable   conservation   in   the   cellular   and   molecular   mechanisms   by   which  
oligodendrocytes  differentiate  and  myelinate  axons  in  both  scenarios  (Fancy,  Chan,  
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Baranzini,   &   Rowitch,   2010;;   Franklin   &   Goldman,   2015).   We   will   first   focus   on  
hypothesis   driven   studies   that   have   identified   regulators   of   remyelination   with  
therapeutic  potential  (Table  1).  See  Box  1  for  overview  of  the  most  commonly  used  
laboratory  models  of  demyelination  referred  to  throughout  this  review.  It  is  essential  
to   note   that   no   currently   available   animal   model   recapitulates   the   complex   and  
divergent  pathogenesis  of  MS.  Individual  experimental  systems  have  complementary  
strengths   and   weaknesses   in   allowing   dissection   of   specific   biological   processes  
associated   with   disease,   e.g.   adaptive   immune   response   against   myelin,   or  
demyelination   with   subsequent   remyelination   (see   Box   1).   This   means   that  
translation   of   interventions   of   therapeutic   potential   from   animal   models   to   human  
represents  a  major  challenge,  as  will  be  discussed  briefly  in  the  next  section.    
Lingo-­1  and  antibody  based  interventions  
Myelin   is   inhibitory   to   axonal   regeneration   in   the   CNS,   an   effect  mediated   in   part  
through  the  action  of  myelin-­expressed  NogoA  on  the  regulation  of  RhoA  activity   in  
axons   (Cao   et   al.,   2010).  NogoA   signals   through   a   receptor   complex   on   the   axon  
containing   the  Nogo-­Receptor,  and  associated   factors  p75  and  Lingo1   (Cao  et  al.,  
2010).  Following   its   identification  as  a   functional   axonal   receptor   linking  Nogo  and  
RhoA-­mediated  growth  arrest  of  axons  during  regeneration  (Mi  et  al.,  2004),  Lingo1  
was   also   found   to   be   expressed   by   oligodendrocytes   (Mi   et   al.,   2005).   This  
suggested   the   hypothesis   that   Lingo1   may   also   negatively   regulate   myelination  
through   RhoA   signalling   in   oligodendrocytes.   Indeed,   overexpression   of   Lingo1  
impaired   myelination,   whereas   abrogation   of   Lingo1   function   accelerated  
oligodendrocyte   differentiation   in   vitro.   Furthermore,   Lingo1  mutant  mice   exhibited  
premature   oligodendrocyte   differentiation   and   myelination   (Mi   et   al.,   2005).   Key  
follow-­up   studies   showed   that   antibodies   directed   against   Lingo-­1   could   improve  
remyelination  following  both  inflammatory  (Mi  et  al.,  2007)  and  Cuprizone-­mediated  
(Mi  et  al.,  2009)  demyelination.  In  fact,  humanised  anti-­Lingo  1  antibodies  have  been  
shown   to   exhibit   a   good   safety   profile   in   humans   and   have   undergone   phase   II  
clinical   trials   for   the   treatment   of   MS.   To   date,   the   results   of   these   trials   appear  
inconclusive,  perhaps  reflecting  the  fact  that  the  anti-­Lingo1  trial  represented  the  first  
ever   trial   that  aimed   to  directly   target   remyelination.  Patient  stratification,   treatment  
dosing,  duration,  and  trial  readouts  remain  important  considerations  for  ongoing  trial  
design   for   those   that   aim   to   assess   how   a   potential   remyelination-­enhancing  
medicine  might   impact   patients  with  MS   (Koch,  Cutter,  Stys,  Yong,  &  Metz,   2013;;  
Plantone,   De   Angelis,   Doshi,   &   Chataway,   2016).   In   particular,   the   ability   to  
conclusively   image   remyelination   in   humans   needs   to   be   fully   realised,   either   by  
MRI-­based   or  PET   ligand-­based  modalities,   and   is   a   topic   of   intense   investigation  
(Absinta,  Sati,  &  Reich,  2016;;  Bodini  et  al.,  2016).  Until  we  have  the  technologies  to  
quantify   remyelination   in   humans,   and   to   assess   associated   functional   output,   our  
ability   to  determine   the  utility   of   remyelination-­enhancing   strategies  will   be  difficult.  
Therefore,  a  major  challenge  in  the  field   is  to  ensure  that  clinical  trial  design  keeps  
pace  with  lab-­based  discoveries  that  generate  leads  of  therapeutic  potential.  
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Interestingly,   antibodies   against   Lingo-­1   are   not   the   only   ones   shown   to   exhibit  
promising  effects  on  myelin  regeneration.  Indeed,  disruption  to  NogoR  itself  has  also  
been   shown   to   improve   remyelination   in   a   toxin-­based   model   of   demyelination  
(Chong   et   al.,   2012),   and   anti-­Nogo   antibody   based   therapies   have   undergone  
phase   I   trials   for   prospective   treatment   of  MS   (Ineichen   et   al.,   2017).   The   biology  
surrounding   the  Nogo-­NogoR/Lingo1   is  complex,   (Schwab,  2010)  as  expression  of  
Lingo1   in   axons   as   well   as   oligodendrocytes   can   inhibit   oligodendrocyte  
differentiation   (X.   Lee   et   al.,   2007),   highlighting   possible   bidirectional   (axon-­
oligodendrocyte)  signalling  between  Nogo  (or  other  ligands)  and  the  NogoR-­Lingo1-­
p75   receptor   complex.   However,   Lingo1   and   Nogo   remain   viable   drug   target  
candidates   for   the   treatment  of  disease.   Indeed,   in  parallel  Nogo/NogoR  remains  a  
target   for   treatment   of   spinal   cord   injury   (Zörner   &   Schwab,   2010),   where   it   is  
possible   that   the   role  of   this   signalling   complex   in   regulating  both  axonal   regrowth  
and   remyelination   may   serve   dual   beneficial   effects.   Interestingly,   another  
recombinant  antibody  (rHIgM22)  originally  derived  from  a  patient  with  Waldenstrom’s  
macroglobulinemia,   has   also   been   shown   capable   of   promoting   remyelination  
following   both   toxin   (Bieber   et   al.,   2002)   and   inflammatory-­mediated   (Pirko   et   al.,  
2004;;  Warrington  et   al.,   2007)   demyelination.  Although   the  molecular  mechanisms  
by   which   this   antibody,   rHlgM22,   functions   are   unclear,   its   promise   in   pre-­clinical  
studies  has   led   to  a  phase   I   clinical   trial   for  prospective   treatment  of  MS   (Kremer,  
Küry,  &  Dutta,  2015).  
Retinoid  X  Receptor  gamma  
Focal   toxin-­induced  demyelination  of   specific  white  matter   tracts  have  proven  very  
useful  for  understanding  the  biology  of  remyelination  in  animal  models,  given  that  the  
precise  timing  of  demyelination  and  remyelination  can  be  well  defined  (Blakemore  &  
Franklin,   2008).   For   example,   the   distinct   phases   of   the   response   to   focal  
demyelination   allowed   Huang   et   al.   to   identify   gene   expression   profiles   that  
characterised   distinct   periods   of   remyelination.   They   hypothesised   that   genes  
differentially   regulated   between   demyelinated   and   remyelinated   lesions   at   specific  
stages  might   include   candidate   regulators   of   remyelination.   Huang   et   al.,   isolated  
lesioned   tissue   at   distinct   stages   following   toxin-­mediated   demyelination   of   the   rat  
cerebellar   caudal   peduncle   and   carried   out   microarray   based   analyses   of   gene  
expression.   Focussing   on   factors   most   highly   upregulated   at   the   stage   when  
remyelination   was   active,   they   identified   the   nuclear   hormone   receptor   Retinoid   X  
Receptor   gamma   as   a   candidate   mediator   of   remyelination   (J.   K.   Huang   et   al.,  
2011).   They   found   that   RXRγ  was   expressed   in   the   oligodendrocyte   lineage,   and  
underwent  a  change   in  subcellular   localisation  upon  oligodendrocyte  differentiation.  
Interestingly,  this  nuclear  to  cytoplasmic  localisation  of  RXRγ  was  severely  disrupted  
in  MS  tissue.  Additionally,  chemical  compounds  known  to  inhibit  RXR  signalling  were  
found  to  impair  oligodendrocyte  differentiation   in  vitro,  while  promoting  its  signalling  
led  to  increased  oligodendrocyte  differentiation.  Most  importantly,  treatment  with  the  
pan-­RXR  agonist,  (targeting  α,  β  and  γ  RXR  forms)  9-­cis-­  Retinoic  acid,  accelerated  
remyelination   in   aged   animals   (J.   K.   Huang   et   al.,   2011).   This   highlighted   the  
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possibility  of  targeting  RXR  to  promote  remyelination  for  the  prospective  treatment  of  
MS.  Indeed,  a  clinical  trial  using  another  pan-­RXR  agonist,  already  approved  for  the  
treatment  of  cutaneous  T-­cell  lymphoma  (Pileri,  Delfino,  Grandi,  &  Pimpinelli,  2013),  
Bexarotene,   is   in   preparation   for   an   MS   trial.   Both   9-­cis-­Retinoic   acid   and  
Bexarotene  are  non-­specific  with  respect  to  agonising  RXR  receptors  α,  β  and  γ,  and  
may   have   side   effects   that   limit   their   long-­term   use,   which   has   driven   studies   to  
identify  isoform-­specific  agonists  of  RXR  subtypes  (Heck  et  al.,  2016).  However,  it  is  
possible   that  pan-­RXR  activation  may  actually  have  beneficial  effects   in  promoting  
remyelination.   In   addition   to   the   possibility   that   its   activation   directly   drives  
oligodendrocyte   differentiation   through   agonising   RXRγ,   activation   of   RXRα   in  
microglia   may   actively   promote   the   clearance   of   myelin   debris   that   results   from  
demyelination   (Natrajan   et   al.,   2015).   The   efficient   clearance   of   myelin   debris   is  
thought  to  represent  another  bottleneck  to  optimal  regeneration  of  myelin  (Kotter,  Li,  
Zhao,  &  Franklin,  2006;;  Kotter,  Setzu,  Sim,  Van  Rooijen,  &  Franklin,  2001;;  Lampron  
et   al.,   2015;;   Safaiyan   et   al.,   2016),   as   discussed   later,   and   thus   promoting   RXR  
signalling  may  help  to  overcome  two  hurdles  to  efficient  remyelination.  
Wnt  pathway  regulation  
Numerous  studies  have  led  to  a  working  model  that  activation  of  the  canonical  Wnt  
signalling   pathway   serves   to   inhibit   oligodendrocyte   differentiation,   and   that   over-­
activation  of  Wnt  signalling  may  block  efficient  remyelination  in  disease  (e.g.  (Fancy  
et   al.,   2009;;   2014;;   2011;;   Rosenberg   &   Chan,   2009)).   Indeed,   small-­molecule  
mediated   inhibition  of  an  enzyme  (tankyrase)   that  stabilises  a  negative  regulator  of  
the  pathway  (axin2),  promotes  remyelination  following  toxin-­mediated  demyelination  
(Fancy  et  al.,  2011).  However,  the  roles  of  Wnt  signalling  in  CNS  (re)myelination  are  
complex   and   potentially   divergent   between   distinct   regions,   over   time,   and   in   the  
context   of   interactions  with   other   cells   and   tissues   (Guo   et   al.,   2015;;   Yuen   et   al.,  
2014).  Furthermore,  the  Wnt  pathway  is  central  to  regulation  of  numerous  biological  
processes  (e.g.  (Bielen  &  Houart,  2014;;  Lambert,  Cisternas,  &  Inestrosa,  2016))  and  
the  consequences  of   its  systemic   targeting  over  prolonged  periods  remain  unclear.  
Therefore,   despite   the   fact   that   numerous   small   molecule   regulators   of   the   Wnt  
pathway  are  available  (B.  Lu,  Green,  Farr,  Lopes,  &  Van  Raay,  2016)  and  represent  
viable   options   for   life-­threatening   conditions   (Tai   et   al.,   2015),   their   utility   for  
treatment  of  a  life-­long  condition  such  as  MS  warrants  careful  consideration.    
Manipulation  of  a  number  of  other  broadly  expressed  factors  have  also  been  shown  
capable  of  promoting   remyelination   in   vivo,   including   interaction  of   the  cholesterol-­
like  molecule  olesoxime  with  the  Mitochondrial  permeability  transition  pore  (Magalon  
et   al.,   2012),   and   the   small   molecule   inhibitor   rolipram   with   Phosphodiesterase-­4  
(Syed  et  al.,  2013)  (Table  1).  The  precise  mechanisms  of  action  of  these  compounds  
on   oligodendrocyte   biology   remain   unclear,   and   thus   whether   the   effects   on  
remyelination  are  direct  or  indirect  is  unknown.    
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G-­protein  coupled  receptors  as  targets  to  promote  remyelination  
A  highly  desirable  attribute  of  a  druggable   target   is   cell   type-­specific  expression   in  
the  target  cell  or  tissue  of  interest.  Cell  type-­specific  expression  of  a  druggable  target  
reduces   concerns   over   unwanted   effects   of   compounds,   e.g.   those   targeting   core  
pathways  shared  across  multiple  cells  and  tissues.  Therefore,  goals  to  identify  genes  
with  cell  type-­specific  expression  in  oligodendrocytes  should  in  principle  lead  to  more  
tractable   targets   for   long-­term  manipulation  of   remyelination,  where   treatment  may  
be  required  over  decades  in  a  disease  like  MS.  
The   transcription   factors   olig1   and   olig2   are   core   regulators   of   the   specification   of  
oligodendrocyte   lineage   cells,   with   olig1   playing   a   specific   and   critical   role   in  
regulating  the  timing  of  myelination  and  remyelination  (Meijer  et  al.,  2012).  Based  on  
the  premise  that  factors  under  the  control  of  olig1  might  identify  targets  that  regulate  
myelination  and  remyelination,  Chen  et  al.,  carried  out  microarray-­based  profiling  of  
gene   expression   in   olig1   mutant   mice.   They   found   that   the   G-­protein   coupled  
receptor   GPR17   was   downregulated   in   expression   by   over   200-­fold   (Chen   et   al.,  
2009).  Given  that  GPCRs  represent  excellent  drug  targets  (Jacobson,  2015;;  Miao  &  
McCammon,   2016),   the   role   of   this   candidate   factor   in   regulating  myelination  was  
investigated.  Expression  analysis  indicated  that  GPR17  was  largely  restricted  to  the  
oligodendrocyte   lineage,   and   it  was   found   that   overexpression   of  GPR17   inhibited  
oligodendrocyte   differentiation,  whereas   its   abrogation  accelerated  oligodendrocyte  
differentiation  and   thus  myelination   (Chen  et  al.,  2009).   Importantly,  a   recent  study  
indicated   that   pharmacological   inhibition   of   GPR17   using   pranlukast   accelerated  
oligodendrocyte  differentiation  following  toxin-­mediated  demyelination,  as  did  genetic  
abrogation  of  GPR17  (Ou  et  al.,  2016).  However,  pranlukast  does  not  specifically  act  
on   GPR17   (Grossman   et   al.,   1997),   but   identification   of   a   specific   antagonist   of  
GPR17  may  represent  a  viable  therapeutic  option  for  enhancement  of  remyelination  
in  the  future.    
Several   GPCRs   are   now   known   to   regulate   myelinating   glial   cell   development  
(Mogha,  D'Rozario,  &  Monk,  2016).  For  example,  GPR37  was  recently  identified  as  
a   potent   negative   regulator   of   oligodendrocyte   differentiation   and   myelination.  
Microarray-­based  profiling  of  isolated  cells  identified  GPR37  as  strongly  enriched  in  
the  oligodendrocyte  lineage.  Highlighting  the  cell  type-­specific  function  of  GPR37   in  
vivo,   constitutive  knockout  of   this  GPCR   lead   to  a  very  specific  phenotype   in  CNS  
myelination.  GPR37  mutant  mice   exhibit   premature   oligodendrocyte   differentiation,  
precocious   myelination,   and   hypermyelination   (H.-­J.   Yang,   Vainshtein,   Maik-­
Rachline,   &   Peles,   2016).   Although   its   role   in   remyelination   has   not   yet   been  
reported,   it   is   possible   that   modulation   of   GPR37   function   could   affect   multiple  
stages   of   myelin   regeneration.   In   addition   to   regulating   oligodendrocyte  
differentiation,   abrogation   of   GPR37   function   could   also   impact   the   extent   of  
myelination  itself,  which  as  we  will  discuss  in  detail  in  a  later  section  is  an  aspect  of  
remyelination   that   has   received   comparatively   little   attention   to   date.   Interestingly,  
GPR37   is   implicated   in   other   diseases   of   the   CNS,   including   Parkinson’s   disease  
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(Murakami  et  al.,  2004)  and  Autism  (Fujita-­Jimbo  et  al.,  2012;;  Tanabe,  Fujita-­Jimbo,  
Momoi,   &   Momoi,   2015),   possibly   due   to   regulation   of   dopaminergic   signalling   in  
neurons   (Marazziti   et   al.,   2007).   Given   its   strong   enrichment   in   expression   in   the  
oligodendrocyte   lineage,   it  will  be   interesting  to  determine  to  what  extent,   if  any,   its  
functional  roles  in  oligodendrocytes  are  relevant  to  these  conditions.  
GPR37   is   closely   related   in   structure   to   another  GPCR,   the   endothelin   receptor  B  
(EdnrB)   (N.   J.   Smith,   2015).   Interestingly,   pharmacological   activation   of   EdnrB  
signalling  can  promote  remyelination   in  an  explant  slice  culture  system,  most   likely  
by   regulating   the   extent   of   myelination   by   oligodendrocytes   (Yuen   et   al.,   2013).  
However,   antagonism  of   both  EdnrA   and  EdnrB   by   a   pan-­antagonist   can   promote  
remyelination   in   vivo   (Hammond   et   al.,   2014),   by   promoting   oligodendrocyte  
differentiation.   It   is  possible   that  different  endothelin   receptors  play  distinct   roles   in  
oligodendrocyte   differentiation   (A)   and   myelination   (B),   and   that   targeting   with  
receptor   specific   antagonists   (A)   and   agonists   (B)   could   synergistically   improve  
remyelination.   The   role   of   another   GPCR,   kappa-­Opioid   receptor,   in   regulating  
remyelination   will   be   discussed   below   in   the   context   of   compounds   identified  
following  an  unbiased  phenotypic  chemical  screen  that  aimed  to  identify  regulators  of  
GPCRs  that  affected  myelination.  
Gli1  
The   signalling   molecule   sonic   hedgehog   (Shh)   is   a   major   regulator   of   many  
biological  processes  (Ferent  &  Traiffort,  2015),  and  activation  of  the  hedgehog  (HH)  
pathway   in   target   cells   activates   Gli   transcription   factors.   Despite   being   a   gold-­
standard   readout  of  HH  pathway  activity,  and  associated  with  glioma   (Rossi  et  al.,  
2011),  the  functional  role  of  Gli1  in  normal  development  and  function  of  the  nervous  
system   remained   elusive   (e.g.   (H.   L.   Park   et   al.,   2000))   until   recently.   Given   that  
previous  studies  had  implicated  neural  stem  cells  (NSCs)  in  the  sub-­ventricular  zone  
as  potential  contributors  to  remyelination  (Nait  Oumesmar,  Picard-­Riera,  Kerninon,  &  
Baron-­Van   Evercooren,   2008),   Samanta   et   al.,   investigated   the   behaviour   of   HH-­
responsive  NSCs  to  demyelination.  To  do  so  they  generated  a  reporter  mouse  based  
on  Gli  activity  to  fate  map  the  response  of  this  subpopulation  of  NSCs  to  cuprizone-­
induced  demyelination  of   the  corpus  callosum.  They   found   that   the  HH-­responsive  
subpopulation  of  NSCs  responded  significantly  to  demyelination  by  generating  OPCs  
that   migrated   to   sites   of   demyelination   and   subsequently   differentiated   into  
oligodendrocytes  that  contributed  to  remyelination  (Samanta  et  al.,  2015).  Somewhat  
surprisingly,   both   genetic   and   small   molecule-­mediated   inhibition   of   Gli1   itself  
promoted  migration  of  OPCs   to  demyelinated  axons,   differentiation  at   lesions,   and  
thus  remyelination.  Interestingly,  this  role  appeared  specific  to  inhibition  of  Gli1  and  
of  a  role  in  HH  signalling,  because  inhibition  of  canonical  HH  signalling  did  not  affect  
remyelination  by  NSCs   (Samanta  et  al.,   2015).  Thus,  despite   the  generality  of  HH  
signalling,   this   surprisingly   specific   function   of   Gli1   may   form   the   basis   of   small  
molecule-­based   targeted   therapies   to   enhance   remyelination.   This   is   further  
substantiated  by  observations  that  Gli1  expression  may  be  transiently  upregulated  in  
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MS   lesions  by   inflammation,  potentially   impairing   regeneration  of  myelin   (Y.  Wang,  
Imitola,  Rasmussen,  O'Connor,  &  Khoury,  2008).  
  
Phenotypic  screens  to  discover  mechanisms  to  promote  remyelination    
In  parallel  to  the  success  of  hypothesis  driven  studies  in  generating  new  targets  and  
compounds   to  promote  myelin   regeneration,  a  set  of   recent  studies  have   taken  an  
unbiased   phenotype-­driven   approach   to   identifying   chemical   modulators   of  
remyelination.  Phenotypic  screens  are  enjoying  something  of  a  renaissance  in  terms  
of  projects  aimed  at   identifying   interventions   to   treat  diseases  of   the  CNS  (Prior  et  
al.,  2014;;  Pruss,  2010).  Indeed,  eight  studies  to  date  have  taken  the  broadly  similar  
approach   of   screening   compound   libraries   for   their   ability   to   promote   the  
differentiation   of   oligodendrocytes   in   vitro   (Deshmukh   et   al.,   2013;;   Joubert   et   al.,  
2010;;  Lariosa-­Willingham  et  al.,  2016;;  Mei  et  al.,  2014;;  Mei,  Mayoral,  et  al.,  2016b;;  
Najm  et  al.,  2015;;  Peppard  et  al.,  2015;;  Porcu  et  al.,  2015)  (Table  2).  The  results  of  
these  studies  have  already  generated  new  compounds  and  targets  of  great  promise  
(see   Tables   1   and   2).   Here   we   will   discuss   some   of   the   salient   issues   regarding  
screen  design  and  execution,  and  then  examine  in  detail  the  hits  identified  in  these  
screens  for  their  ability  to  promote  remyelination  in  vivo.  
The  key  technical  differences  between  the  eight  in  vitro-­based  screens  published  to  
date  can  categorised   into   four  main  areas,  chemical   library  choice,  cell  source  and  
type,  assay  readout,  and  secondary  hit  confirmation.  
Chemical  library  choice  
The   choice   of   chemical   library   is   an   essential   part   in   the   design   of   a   phenotypic  
screen.   This   challenge   is   quite   distinct   from   that   of   library   design   and   selection   in  
more   traditional   drug   discovery   projects   that   focus   on   a   specific   molecular   target  
(Balakin,  Kozintsev,  Kiselyov,  &  Savchuk,  2006).  For  phenotypic  screens   there  are  
advantages  to  using  small  and  well  characterised   libraries  of  compounds,   including  
those  with  drugs  already  approved  for  use  in  man.  The  compounds  in  such  libraries  
often  have  extensive  information  on  their  molecular  target(s),  meaning  that  one  can  
move   towards  mechanistic  studies  of   target   function  more  easily.  Furthermore,   if  a  
hit   compound   is   already   approved   for   treatment   of   another   condition,   a   wealth   of  
information  about   its  safety  profile  and  function   is  available  (Pruss,  2010).This  may  
allow  for  the  rapid  translation  of  findings  into  clinical  trials  with  the  aim  of  repurposing  
compounds  for  the  treatment  of  a  new  disease,  as  has  been  shown  for  one  of  the  hit  
compounds   from   the   following   set   of   screens   (clemastine,   see   below).   However,  
such   an   approach   is   ultimately   limited   in   scope,   as   the   relatively   small   number   of  
such  compounds  means  that  the  same  compound(s)  and  compound  classes  will  be  
identified   when   interrogating   any   biological   process   of   interest.   Therefore,   an  
additional   approach   is   to   screen   larger   and   more   chemically   diverse   libraries   to  
increase  the  chance  of  identifying  new  hits.  This  approach  requires  screening  assays  
that   are   scalable,   and   robust   methods   for   target   deconvolution   to   identify   the  
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mechanistic   action   of   hit   compounds.   Interestingly,   despite   starting   with   different  
libraries,   there  has  been  some  degree   in  overlap  of  compounds  and  target  classes  
identified   in   the  eight  phenotypic  screens   for  oligodendrocyte  differentiation  carried  
out  so  far,  increasing  confidence  in  reproducibility.    
Cell-­type  
Of  the  eight   in  vitro  cell-­based  studies  screening  for  compounds  that  increase  OPC  
differentiation,   four   used   primary   rat   OPCs,   one   used   mouse   epiblast   stem   cell-­
derived  OPCs  and  three  used  immortalised  OPC  cell  lines  from  either  rat  or  mouse.  
Perhaps   the   most   important   difference   is   the   use   of   the   primary   cell   lines   in   the  
Deshmukh,  Mei,  and  Lariosa-­Willingham  studies,  compared  with   immortalised   lines  
used  by  Joubert,  Peppard  and  Porcu.   It   has  been  known   for  over   thirty   years   that  
primary   OPCs   can   differentiate   into   oligodendrocytes   in   culture   in   the   absence   of  
neurons,   (e.g.   (Knapp,   Bartlett,   &   Skoff,   1987;;   Zeller,   Behar,   Dubois-­Dalcq,   &  
Lazzarini,   1985)),   even   to   the   point   of   expressing   differentiated  markers   of  myelin  
and   extending   myelin-­like   membrane   sheets   (Simons,   Krämer,   Thiele,   Stoffel,   &  
Trotter,   2000).   This   default   ability   of   oligodendrocytes   to   differentiate   has   enabled  
screens   using   primary   oligodendrocytes   to   be   carried   out  with   the   knowledge   that  
such  cells  recapitulate  many  aspects  of  physiological  development.  Immortalised  cell  
lines  have  the  advantage  of  being  relatively  homogenous  and  rapidly  expandable  to  
quantities   required   for   high-­throughput   screening,   but   how   closely   they   reflect   the  
biology  of  the  oligodendrocyte  lineage  in  vivo  is  more  questionable.  For  example,  the  
Oli-­neu  line  (used  by  Joubert  et  al.)  does  not  mature  sufficiently  to  robustly  express  
markers   of   myelination   (see   review   by   (Pereira,   Dobretsova,   Hamdan,   &   Wight,  
2011).   Therefore,   Joubert   et   al.   quantified   total   actin-­positive   process   length   as   a  
proxy  of  differentiation  (Joubert  et  al.,  2010).  Porcu  et  al.  also  used  the  Oli-­neu  cell  
line,   but   in   an   attempt   to   overcome   its   limitations,   overexpressed   the   transcription  
factor   MyRF   to   drive   myelin   gene   expression   (Bujalka   et   al.,   2013;;   Emery   et   al.,  
2009),  prior  to  their  screen  (Porcu  et  al.,  2015).  Representing  an  important  additional  
approach   for   the   future,   human   oligodendrocytes   with   physiologically   relevant  
properties   can   now   be   derived   from   both   embryonic   stem   (ES)   (Stacpoole   et   al.,  
2013)  and  induced  pluripotent  stem  (iPS)  cells  (Livesey  et  al.,  2016)  and  generated  
in   sufficient   numbers   for   screens.   In   addition,   compounds   showing   efficacy   in   a  
human  system  would  represent  particularly  promising  candidates  for  prioritisation.    
Assay  design  and  readout  
In  any  chemical  screen,  the  ability  to  identify  true  hits  whilst  minimising  false  positive  
or   false   negative   hits   is   of   utmost   importance.   All   screens  will   identify   some   false  
positives  and  negatives,  however,   the  acid   test  of  a   screen’s   success   is  ultimately  
determined  by  how  many  hits  turn  into  viable  leads  with  translational  potential.  For  a  
screen  to  be  successful,  it  must  begin  with  an  appropriate  assay  design,  including  a  
robust   and   minimally   biased   readout   method.   Each   of   the   eight   in   vitro   OPC  
differentiation  screens  employed  some  form  of  automated  analysis.  Six  of   the  eight  
screens  were  carried  out  using  simple  oligodendrocyte-­enriched  2-­D  cultures  grown  
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in  multi-­well  plate  format,  with  automated  image  acquisition  (Deshmukh  et  al.,  2013;;  
Joubert  et  al.,  2010;;  Lariosa-­Willingham  et  al.,  2016;;  Najm  et  al.,  2015;;  Peppard  et  
al.,  2015;;  Porcu  et  al.,  2015).  Subsequent  image  analyses  included  relatively  simple  
quantification   of   DAPI-­positive   nuclei   surrounded   by   MBP   staining,   as   used   by  
Deshmukh  et  al.,  to  serve  as  a  proxy  for  oligodendrocyte  differentiation.  In  contrast,  
both  Najm  et  al.,  and  Lariosa-­Willingham  employed  more  complex  analyses  of  cell  
morphology   to   estimate   myelin   produced   per   MBP-­expressing   oligodendrocyte,   in  
addition   to   assessing   differentiation.   Finally,   for   the   Joubert   and  Peppard   screens,  
cellular  morphology  alone  was  quantified,  which   in   the  case  of   the  Peppard  screen  
led  to  the  identification  of  1636  primary  hits  from  a  library  of  73,000  compounds.  This  
assay  was  performed  without  replicates,  which  together  with  the  assay  focussing  on  
morphology  alone  as  a  readout,  led  to  a  high  rate  of  false  positives,  as  reflected  by  
the   fact   that   only   22   compounds   ultimately   demonstrated   selective   phenotypes   on  
primary  OPCs   (Peppard   et   al.,   2015).   Therefore,   initial   screen   design   can   help   to  
identify  meaningful  hits  and  prevent  laborious  follow-­up  triaging  studies.  
The   two   screens   carried   out   by   Mei   et   al   employed   a   unique   assay   to   identify  
changes   in   OPC   differentiation,   by   exploiting   the   ability   of   oligodendrocytes   to  
myelinate   inert  objects   (Bechler,  Byrne,  &  Ffrench-­Constant,  2015;;  S.  Lee,  Chong,  
Tuck,  Corey,  &  Chan,  2013;;  S.  Lee  et  al.,  2012a).   In  an  elegant  application  of   this  
observation,   Mei   et   al.   created   a   3D   array   of   conical   fused   silica   micropillars  
arranged  within  a  96-­well   format,  such   that   the  micropillars  acted  as  substrates   for  
rat   OPCs   to   differentiate   upon   and   also   for   oligodendrocytes   to   ensheath   with  
myelinating  processes  (Mei  et  al.,  2014).  By  acquiring   two-­colour  confocal  sections  
through   the   pillar   array,   the   team   were   able   to   quantify   the   relative   proportion   of  
pillars  surrounded  by  distinct   rings  of  MBP-­positive  myelin  membrane  compared   to  
PDGFRα-­positive  OPC  processes.  The   relative  number  of  pillars  positive   for  either  
MBP  or  PDGFRα  was  used  to  assess  the  effect  of  compounds  relative  to  untreated  
controls   (e.g.  more  MBP   rings   suggests  more   differentiation,  more   PDGFRα   rings  
suggests   higher   proportion   of   OPCs).   Thus,   this   two-­colour   fluorescence-­based  
assay   called   the   Binary   Indicant   for  Myelination   using  Micropillar   Arrays,   or   BIMA  
(Mei   et   al.   2014),   allowed   automated   quantitation   ideally   suited   to   large-­scale  
screening  that  could  readily  identify  and  rank  hits  with  a  deceptively  simple  readout.  
Hit  confirmation  and  triaging:  
Following  hit   identification   from  a  chemical   screen,   the  next   step   is   to   confirm  and  
prioritise   hits   for   follow-­up.   Validating   and   characterising   hit   function   within   the  
primary  assay  through  increasing  replicate  number,  performing  simple  concentration  
series  and  assessing  possible  non-­specific  cytotoxicity  are  simple  methods  to  triage  
hits   (Pruss,   2010).   If   hits   have   come   from  well-­annotated   libraries,   then   their   with  
putative  molecular   targets   can   be   assessed   using   either   genetic  manipulations,   or  
more   simply   by   analysing   the   effects   of   additional   compounds   that   hit   the   same  
target.  Ultimately,  to  test  whether  compounds  identified  in  a  cell-­based  screen  might  
have  therapeutic  potential,  validation  in  more  complex  (ideally  multiple)  experimental  
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platforms   is   required.   Such   validation   approaches   were   reported   in   the   studies   of  
Deshmuckh,  Najm  and  both  of  those  by  Mei  et  al.  to  the  point  demonstrating  efficacy  
on  remyelination  in  multiple  in  vivo  models.  
  
Hits   from   phenotypic   chemical   screens   validated   in   vivo   to   enhance  
remyelination  
Validating   the  effects  of   compounds   identified   from   isolated  cell   culture  systems   in  
vivo  is  essential  to  prioritise  hits  for  translation.  Of  the  159  hits  identified  in  the  eight  
in  vitro  OPC  differentiation  screens,  5  have  been  shown  to  improve  remyelination  in  
vivo  thus  far.  
Muscarinic  acetylcholine  receptor  antagonists,  benztropine  and  clemastine  
Given  the  degree  of  overlap  in  libraries  screened  in  the  studies  carried  out  to  date,  it  
is   no   great   surprise   that   they   have   many   hit   compounds   and   target   classes   in  
common.  Among  the  most  consistent   target  class   identified  across  all   the  chemical  
screens   were   muscarinic   acetylcholine   receptors   (mAChRs),   with   antagonists   for  
mAChRs   found  as  hits   in  4  of  7  screens  (Deshmukh  et  al.,  2013;;  Mei  et  al.,  2014;;  
Mei,   Mayoral,   et   al.,   2016b;;   Najm   et   al.,   2015).   In   their   screen,   Deshmukh   et   al.  
identified   six   anti-­cholinergics;;   benztropine,   clemastine,   disopyramide,   trospium,  
diacetyl-­monoxime   and   homatropine,   as   positive   regulators   of   OPC   differentiation.  
They  chose  to  follow  up  benztropine  due  to  its  ability  to  cross  the  blood  brain  barrier  
(BBB),  oral  bioavailability,  and  FDA  approval.  Benztropine  is  a  drug  used  to  manage  
the  symptoms  of  Parkinson’s  disease   (Friedman  et  al.,  1997),  and  so  a  compound  
whose   safety   profile   was   already   well   known,   thus   representing   a   promising  
repurposing   candidate   for   the   treatment   of   MS.   As   with   many   compounds,  
benztropine  acts  on  multiple  targets  and  is  known  to  block  dopamine  re-­uptake  and  
antagonise   the   H1   histamine   receptor   (Agoston   et   al.,   1997;;   McKearney,   1982).  
However,   Deshmukh   et.   al.,   indicated   that   the   pro-­differentiation   effect   on   OPCs  
were   likely   due   to   antagonism  of  mAChRs,   through  a   series   of   co-­treatments  with  
modulators   of   mAChR,   dopamine   and   H1   function.   Importantly,   benztropine   also  
improved   remyelination   in   vivo,   and   increased   oligodendrocyte   differentiation  
following   cuprizone-­mediated   demyelination,   where   treatment   led   to   significantly  
increased  oligodendrocyte  numbers  and  more  myelin  as  assessed  by  luxol  fast  blue  
staining  (Deshmukh  et  al.,  2013).  In  addition,  benztropine  improved  clinical  outcome  
in   a   relapsing-­remitting   EAE   mouse   model,   where   it   also   increased   numbers   of  
mature   oligodendrocytes   and  myelination,   the   latter   assessed  more   definitively   by  
electron  microscopy  (Deshmukh  et  al.,  2013).    
In  agreement,  Mei  et  al.  (2014)  found  that  a  group  of  mAChR  antagonists  increased  
the   percentage   of  MBP-­positive   rings   in   their   BIMA   assay   (Mei   et   al.,   2014).   This  
group   of   hits   correlated   remarkably   with   those   identified   in   the   Deshmukh   et   al.  
screen,  with  clemastine  and  benztropine  appearing   in  both.  Mei  et.  al.   followed  up  
clemastine,   an   FDA   approved   over   the   counter   anti-­histamine   with   an   excellent  
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toxicity   profile   and   CNS   penetrance   (Nicholson,   1985).   Similar   to   benztropine,  
clemastine   improved   remyelination   in  vivo,  using  a   lysolecithin-­induced   focal  spinal  
cord  demyelination  mouse  model  (Mei  et  al.,  2014).  A  follow-­up  study  also  showed  
that  clemastine   improved  clinical  score  and  remyelination   in  EAE,  and,   importantly,  
that   such   remyelination   was   neuroprotective   (Mei,   Lehmann-­Horn,   et   al.,   2016a).  
Furthermore,   oligodendrocyte   specific   knockout   of   the   M1   muscarinic   receptor  
phenocopied   the   effects   of   clemastine   treatment   in   the  EAE  model,   indicating   that  
clemastine   mediates   its   effects   on   remyelination   through   this   receptor   (Mei,  
Lehmann-­Horn,  et  al.,  2016a).  In  a  separate  study,  it  was  shown  that  primary  human  
OPCs  (hOPCs)  also  express  the  M3  muscarinic  receptor,  and  that  treatment  with  the  
M3-­selective  antagonist  soligenacin  could  increase  differentiation  of  isolated  hOPCs  
(Abiraman   et   al.,   2015).   Furthermore,   solifenacin   appeared   to   increase   the  
differentiation   of   hOPCs   transplanted   into   shiverer/   mbp   mutant   mice,   providing  
further   evidence   that   antagonism   of   muscarinic   receptor   function   may   promote  
remyelination   (Abiraman   et   al.,   2015).   In   fact,   given   the   excellent   safety   profile   of  
clemastine,  its  potential  for  repurposing  for  MS  is  already  under  investigation  in  two  
clinical   trials   (optic   neuritis   and   MS,   clinical   trial   references:   NCT02040298   and  
NCT02521311,  respectively).  Intriguingly,  in  another  animal  model  study,  clemastine  
was  found  to  rescue  behavioural  deficits  and  aberrant  prefrontal  cortex  myelination  
found   in   socially   isolated   mice   (Liu   et   al.,   2016),   suggesting   that   promotion   of  
myelination  could  in  principle  be  used  for  the  treatment  of  additional  disorders.  
κ-­opioid  receptor  agonist  (±)-­U-­50488  
Given   the   previously   mentioned   suitability   of   GPCRs   as   drug   targets,   Mei   et   al.  
carried  out  a  second  screen  focusing  on  GPCR  agonists  and  antagonists  using  their  
elegant  BIMA  assay.  From  a  library  of  280  compounds,  they  identified  a  cluster  of  12  
κ-­opioid  receptor  (KOR)  agonists  (out  of  15  hits),  which  promoted  OPC  differentiation  
(Mei,  Mayoral,  et  al.,  2016b).  KORs  are  expressed   in  post-­mitotic  oligodendrocytes  
and   the   best   KOR   agonist   identified   in   their   assay,   (±)-­U-­50488,   increased   the  
proportion   of   MBP-­positive   cells   in   a   purified   OPC   culture   system,   and   promoted  
myelination  in  OPC-­DRG  myelinating  co-­cultures  (Mei,  Mayoral,  et  al.,  2016b).  They  
also   showed   that   the   (±)-­U-­50488  driven   increase   in  OPC  differentiation   in   culture  
was  diminished  using  a  KOR  antagonist,  and  in  mice  lacking  the  KOR.  Importantly,  
Mei   and   colleagues   also   demonstrated   that   (±)-­U-­50488   improved   remyelination  
following   toxin-­induced   demyelination   and   that   this   effect   on   remyelination   was  
absent   in   an   oligodendrocyte-­   specific   KOR   knockout   mouse,   providing   further  
evidence   of   a   direct   effect   of   the   compound   on   the   oligodendrocyte   lineage   (Mei,  
Mayoral,  et  al.,  2016b).  Further  emphasising   the  potential  of   targeting  KOR   for   the  
treatment   of   MS   was   the   parallel   observation   that   (±)-­U-­50488   could   ameliorate  
symptoms  of  EAE  (Du  et  al.,  2016).  
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Glucocorticoid   receptor   agonist   clobetasol   and   miconazole   acting   on   an  
unknown  target    
Two   compounds   from   the  Najm   screen  were   followed   up   in   detail,   clobetasol   and  
miconazole,  both  shown  to  be  effective  at   increasing  oligodendrocyte  differentiation  
in  a  lysolecithin-­induced  mouse  spinal  cord  demyelination  model  (Najm  et  al.,  2015).  
Both  clobetasol  and  miconazole  were  also  shown  to  significantly  improve  the  clinical  
outcome   of   mice   with   a   form   of   EAE   that   aims   to   model   chronic   progressive  MS  
(Najm   et   al.,   2015).   To   identify   the   downstream   targets   of   these   compounds   and  
deduce   their  mechanisms  of   action,  Najm  et.   al.   checked  whether   the   compounds  
acted  on  mAChRs,  before  checking  an  array  of  414  kinases,  but  found  no  changes  
in   activity   with   clobetasol   and   miconazole   treatment.   Next,   they   performed   RNA  
sequencing   and   phospho-­proteomic   analysis   of   treated   versus   untreated   mouse  
OPC   cultures.   In   doing   so,   they   found   that   clobetasol   upregulated   genes  
downstream  of  the  glucocorticoid  receptor.  Following  on  from  this  they  showed  that  
the  glucocorticoid  receptor  was  phosphorylated  upon  treatment  with  clobetasol,  and  
that  clobetasol-­induced  OPC  differentiation,  could  be  blocked  by   the  glucocorticoid  
receptor  antagonist  RU486   (Najm  et  al.,   2015).  Shortly  after   the  Najm  screen  was  
published,  Porcu  et  al.  also  identified  clobetasol  from  their  screen  in  Oli-­neuM  cells  
(Porcu   et   al.,   2015).  Clobetasol,   as  well   as   a   group   of   related   glucocorticoids   had  
previously  been  shown  to  act  as  agonists  for  the  Smoothened  receptor  (J.  Wang  et  
al.,   2010),   and   so   Porcu   et   al.   investigated   whether   its   action   in   regulating   HH  
signalling  was   involved   in   the  pro-­differentiation  effect  of   clobetasol.  By  co-­treating  
OPC   cultures   with   clobetasol   and   smoothened   antagonists   itraconazole   or  
cyclopamine,  they  showed  that  the  increase  in  clobetasol-­driven  OPC  differentiation  
in  vitro  was  significantly  reduced  (Porcu  et  al.,  2015),  suggesting  that  this  may  be  a  
complementary  mechanism  to  the  agonism  of  glucocorticoid  receptors.  It  is  important  
to  note  that  clobetasol  was  also  shown  to  reduce  the  severity  of  a  relapsing-­remitting  
EAE  model  when  administered  prophylactically,  with  this  effect  attributed  to  its  action  
on  T-­cells   (Najm  et  al.,  2015).  Therefore,  clobetasol  may  play   roles   in  multiple  cell  
types  and  through  different  targets  in  biological  processes  of  relevance  to  MS.    
The  molecular  profiling  analysis  by  Najm  et  al.   indicated   that  miconazole   regulates  
myelination   by   increasing   phosphorylation   of   proteins   in   the   mitogen-­activated  
protein   kinase   (MAPK)   pathway,   specifically   through   phosphorylation   of   Erk1   and  
Erk2  (Najm  et  al.,  2015).   Interestingly,  Erk1  and  Erk2  have  recently  been  shown  to  
profoundly  regulate   the  amount  of  myelin  generated  by  oligodendrocytes  (reviewed  
by  (Gonsalvez,  Ferner,  Peckham,  Murray,  &  Xiao,  2015),  suggesting   the  possibility  
that  miconazole  may   also   increase  myelination   per   se.   However,   given   the   broad  
roles  of  the  MAPK  pathway  in  multiple  cells  and  tissues  (Atay  &  Skotheim,  2017),  it  
is  unlikely  that  its  systemic  regulation  represents  a  viable  long-­term  treatment  option  
in  MS.  
In   summary,   recent   cellular-­based   phenotypic   screens   have   identified   numerous  
compounds   and   targets   that   can   promote   remyelination   in   vivo,   one   of   which   has  
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already   led   to   a   drug   repurposing   trial   for   the   treatment   of  MS.   Indeed,   additional  
compounds,  with  roles  in  remyelination  identified  in  other  studies,  are  also  currently  
being  considered  for  repurposing  for  MS,  including  the  anti-­psychotic  quetiapine  (Y.  
Zhang  et  al.,  2012).  Interestingly,  among  its  many  prospective  targets  are  muscarinic  
acetylcholine   receptors,   but   the   side-­effects   and   numerous   targets   of   quetiapine  
(Garver,  2000)  limits  its  attraction  for  treatment  of  MS.  Indeed,  the  fact  that  drugs  are  
already   approved   for   other   conditions  means,   by   definition,   that   they   have   effects  
outwith   those   on   the   oligodendrocyte   lineage.   Therefore,   it   is   hard   to   assess   at  
present   how   many   other   drugs   already   approved   for   use   in   humans   have   true  
potential   for   repurposing   to   promote   remyelination  and   long-­term   treatment   of  MS.  
However,  with  only  a  small  number  of  screens  carried  out  so  far,  significant  success  
has  been  made,  and  new  target  classes  have  been  identified.  Further  assessment  of  
current  hits  and  identification  of  new  hits  from  additional  screens  are  sure  to  provide  
additional   options   for   the   targeted   improvement   of   oligodendrocyte   differentiation  
therapeutically.   However,   as   we   will   discuss   next,   promoting   oligodendrocyte  
differentiation  is  just  one  strategy  to  enhance  remyelination.    
  
Additional  strategies  to  improve  remyelination    
Promoting   recruitment   of   oligodendrocyte   progenitor   cells   to   sites   of  
demyelination  
We   have   focussed   thus   far   on   how   promoting   oligodendrocyte   differentiation  may  
represent  a  potential  treatment  for  MS.  This  is  based  on  the  observation  that  many  
MS   lesions   contain   OPCs   in   sufficient   abundance,   but   that   there   is   an   apparent  
failure   of   these   cells   to   differentiate   into   oligodendrocytes   (A.   Chang   et   al.,   2002;;  
Kuhlmann  et  al.,  2008;;  Lucchinetti  et  al.,  1999;;  Ozawa  et  al.,  1994;;  Wolswijk,  1998).  
However,  many  MS  lesions  completely  lack  OPCs,  indicating  that  their  recruitment  to  
lesions   represents   another   bottleneck   to   regeneration   (Boyd,   Zhang,   &   Williams,  
2013).  OPCs  are  present  in  the  CNS  throughout  life  (Dawson  et  al.,  2003)  and  their  
number   and   distribution   appears   to   be   homeostatically   controlled.   For   example,   in  
both   the   zebrafish   spinal   cord   and   mammalian   cortex,   individual   OPCs   exhibit  
dynamic   behaviour   whereby   they   extend   and   retract   processes   that   interact   with  
those  of   adjacent  OPCs.  When   the  processes  of   neighbouring  OPCs   interact   they  
withdraw   from   one   another   indicating   that   repulsive   interactions   regulate   their  
distribution   (E.   G.   Hughes,   Kang,   Fukaya,   &   Bergles,   2013b;;   Kirby   et   al.,   2006).  
Interestingly,  when  a  small  number  of  OPCs  are  ablated,  neighbouring  OPCs  divide  
and  migrate  to  fill  the  void  (E.  G.  Hughes,  Kang,  Fukaya,  &  Bergles,  2013b;;  Kirby  et  
al.,   2006).   Homeostasis   of   OPCs   can   also   be   seen   at   the   wider   population   level.  
Despite  impairing  the  proliferation  of  90%  of  adult  OPCs  through  genetic  targeting,  it  
was   recently  observed   that   the   remaining  non-­recombined  cells   could   compensate  
and   proliferate   such   that   total   OPC   number   was   maintained   at   the   normal   level  
(Schneider  et  al.,  2016).  This  homeostatic  propensity  of  OPCs  indicates  that  this  cell  
population  is  tractable  for  expansion  and  mobilisation  to  MS  lesions  where  they  are  
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absent.   However,   there   are   numerous   environmental   features   that  may   limit   OPC  
recruitment  to  MS  lesions.  It  has  been  shown  that  expression  of  semaphorins  known  
to   regulate   developmental   OPC   migration   (Sema   3A   and   3F)   are   differentially  
upregulated   in   distinct   MS   lesions   (Williams   et   al.,   2007).   Experimental   studies  
indicate   that  Sema  3A  prevents  OPC   recruitment   to  demyelinated   lesions  and   that  
Sema  3F  can  attract  OPCs  to  lesions  (Piaton  et  al.,  2011).  These  data  indicate  that  
manipulation  of  semaphorins  or  their  receptors  may  overcome  impaired  recruitment  
of  OPCs  to  MS  lesions.  Studying  OPC  migration  in  the  context  of  demyelination  for  




Regeneration  of  myelin  sheaths  of  optimal  size  
The   recently  published  phenotypic  chemical   screens  described  above  highlight   the  
value  of  simple  cell-­based  assays  for  identifying  compounds  that  promote  a  singular  
process   i.e.   oligodendrocyte   differentiation.   While   the   rationale   of   promoting  
oligodendrocyte   differentiation   to   enhance   remyelination   in   MS   has   become   the  
central   focus   of   recent   strategies,   it   remains   to   be   seen   to   what   extent   the  
compounds  and  targets   identified  using  this  approach   improve  functional  outcomes  
for   patients.   For   example,   whether   health   and   function   is   truly   restored   to  
remyelinated   axons   in   humans   remains   to   be   tested.   Indeed,   it   is  well   known   that  
even   in   areas   of   significant   remyelination,   in   both   MS   and   animal   models,  
remyelination   is   imperfect,  whereby   the  myelin  sheaths   formed  during  regeneration  
are   shorter   and   thinner   than   normal   (Blakemore,   1974;;  M.   B.   Bunge   et   al.,   1961;;  
Gledhill   et   al.,   1973;;   Prineas   &   Connell,   1979).   Given   increasing   evidence   that  
precise   regulation   of   the   number,   length   and   thickness   of   myelin   sheaths   along  
axons   is   likely   to   fine-­tune   neuronal   circuit   function   (Baraban   et   al.,   2016;;   Fields,  
2015;;   Seidl,   2014),   it   is   not   unreasonable   to   suggest   that   regeneration   of   myelin  
sheaths   of   normal   parameters   is   desirable   (Filley   &   Fields,   2016;;   Liebetanz   &  
Merkler,  2006).  Indeed,  it  is  possible  that  restoration  of  normal  myelin  sheaths  during  
remyelination   might   be   an   important   goal   to   consider   with   the   aim   of   tackling  
cognitive   impairments   associated   with   MS.   Given   the   additional   trophic   and  
metabolic  support  functions  of  myelin  (Fünfschilling  et  al.,  2012;;  Y.  Lee  et  al.,  2012b;;  
Nave,  2010;;  Saab  et  al.,  2013),  it  is  also  plausible  that  the  restoration  of  sheaths  of  
normal   size   may   be   required   to   reinstate   these   roles   optimally,   and   perhaps   to  
provide  best  protection  to  axons  from  prospective  degeneration.    
Whereas  oligodendrocytes  have  an  inherent  capacity  to  differentiate   in  vitro,  myelin  
sheath   formation   necessarily   requires   an   axon,   or   an   axon-­like   physical   substrate  
(Bechler   et   al.,   2015;;   S.   Lee   et   al.,   2012a;;   Lubetzki   et   al.,   1993).   Therefore,   the  
previous   screens   that   identified   multiple   pro-­differentiating   compounds   did   not  
assess  myelination   per   se.   Emerging   data   now   indicate   that   a   combination   of   the  
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physical   size   (diameter)   of   axons   (Almeida,   Czopka,   Ffrench-­Constant,   &   Lyons,  
2011;;  Bechler  et  al.,  2015;;  Goebbels  et  al.,  2016;;  S.  Lee  et  al.,  2012a)  and  axonal  
signals   (e.g.   (Gibson   et   al.,   2014;;   Koudelka   et   al.,   2016)),   cooperate   to   regulate  
myelin  sheath  number,  length,  and  thickness  along  CNS  axons  (see  (Klingseisen  &  
Lyons,   2017)   for   review).   Why   myelin   sheaths   appear   to   be   shorter   and   thinner  
during   default   remyelination   remains   unknown.   However,   the   process   of  
remyelination  can  in  principle  restore  myelin  sheaths  of  normal  thickness  and  length  
to   axons   (Fyffe-­Maricich,   Schott,   Karl,   Krasno,   &   Miller,   2013;;   Münzel,   Becker,  
Becker,  &  Williams,   2014;;  Powers   et   al.,   2013;;  Xing   et   al.,   2014),   suggesting   that  
identification  of  mechanisms  that  regulate  these  parameters  could  lead  to  strategies  
to  optimally  regenerate  myelin.  Although  we  are  now  starting  to  gain  insight  into  the  
mechanisms  that  regulate  myelin  sheath  growth,  such  studies  are  typically   in-­depth  
phenotypic   analyses   that   are   not   readily   suited   for   large-­scale   drug   discovery.  
Therefore,   robust   and   reductionist   automated   assays   to   study   axon-­myelin  
interactions  with  sufficient  scale  are  required.  
  
Additional  opportunities  to  treat  the  progressive  stages  of  MS    
The   enhancement   of   oligodendrocyte   differentiation   represents   one   opportunity   to  
promote   the   regeneration   of   myelin   for   the   treatment   of   MS.   In   addition   to   direct  
manipulation  of  the  oligodendrocyte  lineage,  it  is  clear  that  axons,  neural  stem  cells,  
microglia/  macrophages,  Schwann  cells,  astrocytes,  cells  of  the  vasculature,  as  well  
as  additional  innate  and  adaptive  immune  cells,  are  also  likely  to  represent  possible  
therapeutic  targets  for  the  treatment  of  the  progressive  stages  of  MS.  Consideration  
of   the   diverse   pathologies   of   MS   and   potential   strategies   and   entry-­points   for   its  
treatment  are  beyond  the  scope  of  this  review,  but  have  been  extensively  described  
and   reviewed   elsewhere   (Barnett   &   Linington,   2013;;   Correale   &   Farez,   2015;;  
Dombrowski  et  al.,  2017;;  Domingues,  Portugal,  Socodato,  &  Relvas,  2016;;  Franklin  
&  Goldman,  2015;;  Liddelow  et  al.,  2017;;  Lloyd  &  Miron,  2016;;  Nait  Oumesmar  et  al.,  
2008;;   Ransohoff,   Hafler,   &   Lucchinetti,   2015a;;   Ransohoff,   Schafer,   Vincent,  
Blachère,   &   Bar-­Or,   2015b;;   Waxman,   2008;;   Yuen   et   al.,   2014;;   Zawadzka   et   al.,  
2010).    In  the  final  section  of  this  review  we  focus  on  emerging  technologies  that  will  
play   important   roles   in   dissecting   the   basic   biology   of   disease   and   in   providing  
platforms  that  allow  screening  for  drug  discovery.  
  
Cutting  edge  technologies  to  understand  glial  function,  cell-­cell  interactions,  
and  drive  drug  discovery  
The   phenotypic   cell-­based   assays   discussed   at   the   beginning   of   this   review   focus  
entirely   on   oligodendrocyte   lineage   cells   in   isolation.   In   doing   so,   they   lack   the  
fundamental   physical   substrate   required   for   the   process   of   myelination,   axons,   in  
addition   to   the   dynamic   communication   that   occurs   between  oligodendrocytes   and  
their  surrounding  microenvironment.  A  number  of  current  and  emerging  technologies  
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are   providing   new   possibilities   for   studying   cell-­cell   interactions   in   vitro   using  
platforms   that   more   closely   resemble   the   in   vivo   environment.   In   the   following  
sections,  we  will  discuss  the  expanding  field  of  microfluidics  and  how  miniaturisation  
of   liquid-­delivery   systems   is   improving   the   spatiotemporal   control   of   drug   delivery.  
We  will   then  consider  how  this   technology  has  been   integrated  with  co-­culture  and  
organotypic   slice   culture   preparations   to   study   the   processes   of   de-­   and  
remyelination   in  vitro  before  focusing  on  recent  advancements  in  disease  modelling  
and  drug  development  using  3D  organoids,  and  “organs-­on-­chip.”    
Microfluidics  
Microfluidics,  or  chip-­based  miniaturized  fluid  handling  systems  is  a  technology  that  
has   greatly   expanded   over   the   last   couple   of   decades.   Originally   developed   from  
fabrication  technologies  within  the  microelectronics  industry,  it  has  advanced  into  an  
interdisciplinary  field  that  aims  to  model  physiological  microenvironments  through  the  
use   of   engineered   platforms   (Manz,   Graber,   &   Widmer,   1990).   At   the   heart   of  
microfluidics   is   the   ability   to   manipulate   the   flow   of   fluids   within   engineered  
microchannels.   A   variety   of   fabricated   designs   have   been   developed   that   enable  
multiple   cell   types   to   be   either   cultured  within   a   single   compartment   or   separated  
across  multiple   chambers   inter-­connected   by  microchannels,   some   of   which   have  
been  applied  to  the  co-­culture  cells  of  the  nervous  system  (Neto  et  al.,  2016).  
Modelling  myelination  with  microfluidics  
Multi-­compartment   microfluidic   devices   composed   of   separate   neuronal-­soma   and  
axon-­glia  compartments  connected  via  microchannels  have  been  fabricated  to  study  
myelination.  In  one  of  the  first  designs,  neurons  cultured  in  a  central  soma  chamber  
extended   axons   along   arrays   of   microchannels   into   separate   glia   compartments  
containing  oligodendrocytes   (J.  Park,  Koito,  Li,  &  Han,  2009).  Although   this  design  
only   permitted   a   single   treatment   to   be   applied   across   the   entire   platform,   more  
recent   systems   allow   independent   fluid   control   to   separate   neuron   and   glial  
compartments  (Majumdar,  Gao,  Li,  &  Webb,  2011)  or  to  multiple  glial  compartments  
in  parallel  enabling  the  effects  of  compounds  on  specific  cell  types  to  be  studied  (J.  
Park,  Koito,  Li,  &  Han,  2012).   In   these  examples,  cultured  OPCs  differentiated   into  
mature  OLs,  as  assessed  by  MBP  expression,  and  were  shown  to  form  sheath-­like  
structures   resembling   myelin   around   axons   (Kerman   et   al.,   2015;;   J.   Park   et   al.,  
2012).  
A  challenge  associated  with   the  use  of  microfluidics   in  high-­throughput  myelination  
screening  is  accurately  quantifying  myelin  sheath  formation  in  response  to  chemical  
treatments  (Kerman  et  al.,  2015).  Previous  co-­culture  studies  have  relied  on  manual  
approaches   to   count   or   trace   individual   MBP+   segments   of   myelin   following   drug  
treatments  (I.  H.  Yang  et  al.,  2012).  Apart  from  being  incredibly  time-­consuming  and  
limited   to   small-­scale   comparisons   of   chemical   treatments,   these   approaches   are  
also  inherently  subjective.  Therefore,  the  development  of  computational  approaches  
for   the   accurate,   automated   analysis   of   myelination   are   paramount.   Zhang   et   al.  
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were   the   first   to   use   a   computational   approach   based   on   the   overlapping  
fluorescence  of  myelin,  visualised  with  MBP  staining  and  axons,  using  Neurofilament  
staining,   respectively,   to   quantify   myelination   per   axonal   area   (H.   Zhang,   Jarjour,  
Boyd,  &  Williams,   2011).  Using   this   as   an   index   of  myelination,   they  were   able   to  
show  that  treatment  with  factors  reported  to  affect  myelination  and  re-­myelination  in  
vivo  had  a  similar  effect   in  a  cerebellar  slice  culture  model  (H.  Zhang  et  al.,  2011).  
Taking   a   similar   fluorescence   co-­localisation   approach,   Kerman   et   al.   reported   a  
semi-­automated  method  for  myelin  quantification  in  a  microfluidic  co-­culture  system  
that  could  be  applied  to  large  datasets  (Kerman  et  al.,  2015).    
One  interesting  application  of  microfluidic  co-­culture  devices  could  be  for  the  study  of  
neuronal   activity-­dependent   regulation   of   myelination.   In   a   report   by   Yang   et   al.,  
applying  intermittent  electrical  stimulation  to  DRG-­glia  microfluidic  cultures  (1hr/day)  
induced   a   five-­fold   increase   in   the   number   of  myelin   segments,   confirmed   by  EM.  
This  data  suggests  that  the  neuron-­glia  communication  events  that  mediate  activity-­
dependent  myelination  as  reported  in  vivo  may  also  be  conserved  in  vitro  and  could  
allow   for   the   careful   dissection   of   neuronal   versus   oligodendrocyte   components   of  
this  process  (Gibson  et  al.,  2014;;  Hines,  Ravanelli,  Schwindt,  Scott,  &  Appel,  2015;;  
Koudelka  et  al.,  2016;;  Mensch  et  al.,  2015;;  I.  H.  Yang  et  al.,  2012).  This  finding  was  
further   exemplified   in   a   recent   study   whereby   optical   stimulation   of   neurons  
expressing   light-­sensitive   ion   channels   within   microfluidic   chambers   resulted   in  
increased   numbers   of   myelin   sheath   structures   (H.   U.   Lee   et   al.,   2016).   While  
vesicular-­mediated   signalling   between   neurons   and   oligodendrocytes   has   been  
reported  (Frühbeis  et  al.,  2013;;  Hines  et  al.,  2015;;  Koudelka  et  al.,  2016;;  Mensch  et  
al.,  2015;;  Wake,  Lee,  &  Fields,  2011;;  Wake  et  al.,  2015),  the  exact  signalling  events  
underlying  activity-­dependent  regulation  of  myelination  are  still  unknown.  Therefore,  
the   accessibility   of   microfluidic   systems   to   biochemical   analysis   of   isolated   tissue  
(Taylor  et  al.,  2005),  electrophysiological   recording   (Biffi  et  al.,  2012)  and   localised  
delivery  of  neuromodulators  provide  an  exciting  platform   in  which   this  process  can  
be  studied.    
The   small   dimensions,   low   sample   consumption,   potential   for   automated   analysis  
and   parallelisation   make   microfluidic   devices   particularly   attractive   for   high-­
throughput   drug   screening.   While   the   number   of   reported   microfluidic   culture  
systems   for   investigating   neuronal   and/or   glial   drug   responses   is   increasing,  
throughput   still   lags  behind   that   of   conventional  multi-­well   cell   cultures   (H.  S.  Kim,  
Jeong,  Koo,  Han,  &  Park,  2016).  
Organotypic  slice  cultures  
Isolated  living  slices  of  brain  tissue  provide  valuable  ex  vivo  models  given  that  they  
retain   tissue   architecture   and   circuit   connectivity   from   their   source   of   origin.   In  
addition,   with   most   of   the   major   cell   types   present,   the   effect   of   exogenous  
treatments   on   the   physiology   of   the   tissue   as   a  whole   can   be   investigated.  Major  
improvements   in   preservation   have   meant   that   organotypic   slice   cultures   can   be  
maintained   for   several   weeks   to   months   in   vitro   via   perfusion   with   oxygenated  
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artificial  cerebrospinal  fluid,  enabling  long-­term  live  imaging  and  electrophysiological  
recording  (S.  Cho,  Wood,  &  Bowlby,  2007;;  Gogolla,  Galimberti,  DePaola,  &  Caroni,  
2006).  These  advantages  make  organotypic  slice  cultures  a  useful  model  system  in  
which  to  investigate  responses  to  chemical  treatments.    
Studying  de-­  and  re-­myelination  in  organotypic  slice  cultures  
While  in  vitro  co-­culture  studies  of  myelination  provide  great  flexibility  in  terms  of  the  
genetic  background  of   the  cells  used  (e.g.  combining  mutant  neurons  with  wildtype  
oligodendrocytes  and  vice  versa),  ex  vivo  organotypic  slice  cultures  largely  retain  the  
cellular   environment   in   which   myelination   occurs   in   vivo   (for   review   see   (Jarjour,  
Zhang,   Bauer,   Ffrench-­Constant,   &   Williams,   2012)).   Using   viral-­mediated   gene  
delivery   of   fluorescent   proteins   to   label   oligodendrocytes   within   slice   cultures,   the  
structural   dynamics  and  behaviour   of   individual   oligodendrocyte   lineage  cells   have  
been   followed  during   their  migration  and  maturation   (Haber,  Vautrin,  Fry,  &  Murai,  
2009).   Over   time,   endogenous   oligodendrocytes   within   these   cultures   form  
membrane   ensheathments   around   axons   which   are   both   positive   for   the   myelin  
marker  mbp  and  form  clear  myelin  sheaths  (H.  Zhang  et  al.,  2011).  This  attribute  of  
organotypic   slices   has   been   exploited   to   investigate   the   processes   of   de-­   and  
remyelination  in  vitro.  Although  a  number  of  methods  have  been  used  to  demyelinate  
axons  within  slice  cultures,  one  of  the  most  characterised  is  that  of  treatment  with  the  
gliotoxin  lysophosphatidylcholine  (LPC)  (H.  Zhang  et  al.,  2011).  In  2004,  Birgbauer  et  
al  were  the  first  to  demonstrate  remyelination  of  axons  following  LPC  treatment  in  a  
cerebellar   slice   culture   model   (Birgbauer,   Rao,   &   Webb,   2004).   While   this  
manipulation  does  not  model   the   inflammatory  pathology  of  MS,   the  proliferation  of  
OPCs   following   demyelination   and   the   production   of   thinner   myelin   with   shorter  
internodes   is  characteristic  of   that  seen   in  vivo   (H.  Zhang  et  al.,  2011).   In  addition,  
many   compounds   shown   to   improve   remyelination   in   vivo,   have   demonstrated  
similar  effects  following  LPC-­induced  demyelination  of  cerebellar  or  spinal  cord  slice  
cultures  validating  these  models  for  the  characterisation  of  remyelination-­enhancing  
therapeutics  (e.g.  (J.  K.  Huang  et  al.,  2011;;  Mei  et  al.,  2014;;  Najm  et  al.,  2015)).  The  
possibility   to   carry   out   focal   demyelination   in   slice   cultures  may  also  allow  ex   vivo  
analyses   of   OPC   recruitment   to   lesions,   which   may   provide   an   important  
experimental  platform  to  interrogate  further  mechanisms  relevant  to  overcoming  this  
bottleneck  to  regeneration.  
While   these   experiments   highlight   the   value   of   slice   culture   models   for   drug  
screening,   the   throughput   of   such   systems   is   invariably   low   compared  with   that   of  
cell-­based   assays.   This   is   in   part   due   to   the   practical   limitations   of   the   slice  
preparation  in  addition  to  the  lack  of  standardised  perfusion  systems  for  the  local  and  
stable   application  of   drugs   to   slices.  For   these   reasons,   slice   culture  models   have  
mostly   been   used   as   secondary   assays   to   pre-­select   promising   therapeutics   for  
further   in   vivo   analysis.   Recently,   organotypic   slice   cultures   have   been   integrated  
within   microfluidic   systems   enabling   greater   control   over   drug   delivery   and   the  
potential  for  increased  scalability.  
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Combining  microfluidics  with  organotypic  slice  cultures  
In   2009,   Berdichevsky   et   al,   published   one   of   the   first   compartmented   culture  
devices  that  allowed  organotypic  slice  cultures  to  be  maintained  within  a  microfluidic  
platform.  In  this  system,  individual  slices  cultured  within  separate,  fluidically-­isolated  
compartments   extended   axons   along   connecting   microchannels   to   form   synaptic  
connections   with   axons   from   the   neighbouring   slice.   Using   slice   cultures   from   the  
entorhinal   cortex   and   hippocampus,   functional   synapses   were   reported   to   form  
between   the   two   brain   regions   enabling   synchronization   of   network   activity   across  
the   two-­slice   network.   Additionally,   selective   pharmacological   modulation   to   block  
spontaneous  activity  within  one  slice  could  be  applied  without  affecting  the  activity  of  
the   other   (Berdichevsky,   Sabolek,   Levine,   Staley,   &   Yarmush,   2009).   While   this  
study   demonstrated   the   potential   of   microfluidic   slice   culture   systems   for  
investigating   circuit-­specific   effects   following   chemical   treatments,   it   was   limited   in  
throughput   to   one   chemical   treatment   per   slice.   Recently,   a   microfluidic   system  
allowing   multiple   drug   responses   to   be   assessed   in   parallel   was   reported   (T.   C.  
Chang   et   al.,   2014).   Using   a   spatially-­defined   network   of   microchannels,   multiple  
compounds  were   delivered   simultaneously   to   pre-­defined   locations   within   a   single  
mouse  brain  slice.  Treatment  with  a  concentration  series  of  the  cytotoxic  agent  STS  
demonstrated  significant  cell  death  selectively  in  STS-­treated  areas,  which  increased  
in   a   dose-­dependent   manner   (T.   C.   Chang   et   al.,   2014).   Intended   primarily   for  
assaying   chemotherapeutics,   the   benefits   of   this   system   could   be   applied   to   the  
cytotoxicity   profiling   of   compounds,   more   generally   providing   a   means   by   which  
small   libraries  of  compounds  could  be  assayed  relatively  quickly   for  unwanted  side  
effects.    
While  these  rodent-­based  models  provide  valuable  model  systems,  the  possibility  of  
studying   a   patient’s   own   tissue   may   give   unprecedented   insight   into   disease  
development  and   the  effects  of  potential   therapeutics,  a  possibility   that   is  currently  
being  realised  with  3D  organoid  technology.  
Studying  the  CNS  microenvironment  using  3D  organoids  
As  previously  highlighted,  the  complexity  of  the  CNS  can  be  defined  not  only  by  the  
diverse  array  of  cell  types  and  extensive  communications  that  occurs  between  them  
but   also   by   the   highly   organised   arrangement   of   these   cells   within   the   3D  
environment.  A  recent  approach  to  mimic  this  environment  in  vitro  through  the  use  of  
3D   organoid   cultures   has   created   new   possibilities   to  model   CNS   physiology   and  
disease  with   remarkable   fidelity   (Shamir  &  Ewald,  2014).  3D  organoids  have  been  
generated  using  a  variety  of  different  protocols,  however,   they  generally   rely  either  
on  external  patterning  growth  factors  to  direct   formation  of  specific  brain  regions  or  
utilise  self-­patterning  and  self-­organisation  principles  in  an  effort  to  mimic  those  used  
by  the  brain  during  embryonic  development  (Eiraku  et  al.,  2011).   Initially  generated  
using   rodent   embryonic   stem   cells   (Eiraku   et   al.,   2008),   recent   advancements   in  
human   stem   cell   culture   have   enabled   the   generation   of   3D   organoids   from  
pluripotent  human  embryonic  stem  cells,  multipotent  somatic  stem  cells  and  induced-­
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pluripotent   stem   cells   (iPSCs)   allowing   expansion   directly   from   patient   tissue  
(Lancaster  et  al.,  2013).  In  addition,  strategies  for  re-­programming  iPSC  cells  into  all  
major  cell  types  of  the  nervous  system  including  neurons  (Hunsberger  et  al.,  2015),  
oligodendrocytes   (Prasad   et   al.,   2016),   astrocytes   (Jiang   et   al.,   2016;;   Zhou   et   al.,  
2016),   and   microglia   (Muffat   et   al.,   2016)   have   been   developed   providing   an  
invaluable   resource   for   studying   human   neurological   disease.   Using   these  
techniques,  protocols   for   the  generation  of  human  brain-­like  cerebral   (Lancaster  et  
al.,   2013),   cerebellar   (Muguruma,   Nishiyama,   Kawakami,   Hashimoto,   &   Sasai,  
2015),   forebrain   (Qian   et   al.,   2016)   and  mid-­brain   (Jo   et   al.,   2016;;  Monzel   et   al.,  
2017)  organoids  have  been  reported.    
3D  organoids  for  disease  modelling  
A  small  number  of  studies  have  already  begun  to  investigate  the  potential  of  patient  
iPSC-­derived  3D  organoid  cultures  to  model  disease  (Lancaster  et  al.,  2013;;  Raja  et  
al.,  2016)  (Lancaster  et  al.  2013;;  Raja  et  al.  2016).  Lancaster  et  al.,  showed  that  iPS  
cells  derived  from  a  patient  with  severe  microcephaly  formed  3D  cerebral  organoids  
with  smaller  neural  tissues  and  progenitor  zones  reflective  of  the  reduced  brain  size  
of   the  patient   (Lancaster   et   al.,   2013).  Similarly,   iPS   cells   generated   from  patients  
with  familial  AD  were  reported  to  recapitulate  many  AD-­like  pathologies,  such  as  β-­
amyloid  aggregation,  hyper-­phosphorylated  tau  protein  and  endosome  abnormalities  
that  are  commonly  missing   from  2D  cultures   (Raja  et  al.,  2016).  One  concern  with  
using   3D   organoid   models   is   that   their   size   may   reduce   compound   penetration.  
However,  in  the  latter  study,  treatment  with  β-­  and  γ-­  secretase  inhibitors  was  shown  
to   reduce   both   the   number   of   β-­amyloid   aggregates   and   level   of   pTau  
immunoreactivity  suggesting  that  these  model  systems  could  be  a  potential  avenue  
for  drug  testing  (Raja  et  al.,  2016).  While  many  features  of  the  human  brain  such  as  
the  3D  stereotypical  cytoarchitecture  and  electrophysiological  properties  have  been  
recapitulated  in  these  models,  at  least  in  part  (Lancaster  et  al.,  2013;;  Monzel  et  al.,  
2017;;  Muguruma  et  al.,  2015),  the  presence  and  function  of  glial  cell  types  remains  
understudied.  However,  a  recent  study  describing  the  development  of  a  3D  midbrain-­
like   organoid   for   the   analysis   of   Parkinson’s   disease   (PD),   reported   expression   of  
S100β  and  CNP-­positive  cells,   indicative  of  astrocytes  and  oligodendrocytes  within  
mature   organoids   (Monzel   et   al.,   2017).   In   addition,   3D   immuno-­reconstructions  
revealed   areas   of   CNP-­positive   staining   that   appeared   to   ensheath   neurites  
suggesting   that  differentiated  oligodendrocytes  may   functionally  myelinate  axons   in  
3D  culture.  Although  further  work  will  be  required  to  fully  characterise  glial  cell  types  
within   these  models,   if   they  do  recapitulate  cell   function   in  vivo,  3D  organoids  may  
provide   a   means   to   investigate   the   mechanisms   of   myelin   dysregulation   using  
patient-­derived  cells.   In  addition,   this  creates  new  opportunities   for  phenotypic  and  
mechanistic  drug  screening  in  complex  human  disease  models.  
While   it   is  clear   that   the  3D  complexity  and   relative  ease  with  which  3D  organoids  
can  be  generated  represent  significant  advantages,  do  they  represent  useful  models  
for   high-­throughput   drug   screening?   In   the   following   sections,  we  will   suggest   that  
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the   recent   integration  of  3D  organoids  within  miniaturised  chips,   termed   ‘organ-­on-­
chip’  technology  has  the  potential  to  become  a  powerful  tool  for  drug  discovery  and  
development.  
Organs-­on-­chips  
Integration  of   cutting  edge   innovations   in  microfluidics,  3D  cell   culture,   vasculature  
modelling  and  micro  sensors   for  electrophysiological  and  biochemical  analyses  are  
transforming   the   way   in   which   we   study   basic   physiology   and   drug   development.  
These  new  in  vitro  models,  termed  “organs-­on-­chips”  may  not  necessarily  mimic  the  
function  of  an  entire  organ,  but  rather  recapitulate  specific  aspects  of  its  function  on  
a   single   mm-­sized   device.   Through   reproducing   organ-­specific   3D   structure,  
microenvironment   and   physiology,   a   number   of   devices   have   been   generated   to  
mimic  the  lung,  heart,  kidney,  liver,  intestine  and  brain  (Agarwal,  Goss,  Cho,  McCain,  
&  Parker,  2013;;  Choucha  Snouber  et  al.,  2013;;  Huh  et  al.,  2010;;  H.  J.  Kim  &  Ingber,  
2013;;   Schwartz   et   al.,   2015).   These   platforms   not   only   allow   visualisation   of  
dynamic,   organ-­level   responses   that   cannot   normally   be   observed   in   conventional  
2D  cell  culture  modes,  but  can  also  be  used  to  facilitate  drug  development.  Many  hit  
compounds  fail  during  clinical  testing  due  to  poor  efficacy,  unexpected  adverse  drug  
effects  and  poor  blood  brain  barrier  (BBB)  permeability  leading  to  costly  withdrawals  
(Esch,  Bahinski,  &  Huh,  2015).  Therefore,   improving  the  effectiveness  of  preclinical  
testing  to  better  predict  human  drug  responses  is  of  critical  importance.  
Improving  drug  development  with  organs-­on-­chips  
One  recent  use  of  organ-­on-­chip  systems  is  in  preclinical  pharmacokinetic  (PK)  and  
pharmacodynamic  (PD)  modelling  of  drugs.  Determining  how  much  of  a  compound  
will  reach  its  physiological  target  in  vivo,  and  the  final  pharmacological  effect  is  a  vital  
stage   in   drug   development   and   is   normally   carried   out   through   mathematical  
modelling.  However,  for  these  models  to  be  predictive,  they  require  accurate  in  vitro  
data  on  drug  metabolism  and  physiology  (J.  B.  Lee  &  Sung,  2013).  Conventional  2D  
cell  cultures  are  unable  to  capture  the  dynamic  complexity  of  human  drug  responses  
often   resulting   in   model   predictions   that   are   wholly   inaccurate   when   tested   in  
humans.   Through   using   organ-­on-­chip   technology,   whereby   multiple   fluidic  
compartments   each   holding   a   single   biomimetic   organ   can   be   inter-­connected,  
physiologically-­relevant  data  on  model  multi-­organ   interactions  can  be  obtained   (J.  
B.  Lee  &  Sung,  2013).  In  addition,  organ-­on-­chip  technology  could  reduce  the  need  
for   whole   animal   testing.   Generally,   safety   and   toxicity   testing   are   carried   out   in  
whole  animals  prior   to   clinical   testing   in   humans.  However,   these  experiments  are  
slow,   costly,   require   significant   amounts   of   compounds   and   cross-­species  
differences  can  often  result   in  false  positives.  Therefore,  using  human-­derived  cells  
on  3D  microplatforms  may  be  one  method  by  which  the  validity  of  toxicity  testing  can  
be  improved,  while  minimising  animal  usage,  cost  and  reagent  volumes  (Crofton  et  
al.,  2011).    
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Modelling  the  BBB  with  organ-­on-­chip  technology  
Dysfunction  of   the  BBB   is  at   the  centre  of  a  number  of  diseases   including  MS.  An  
early   event   in   relapsing-­remitting   forms   of   MS   is   hyperpermeability   of   the   BBB  
resulting  in  increased  migration  of  peripheral  immune  cells  into  the  CNS  which  both  
increases   inflammation   and   exacerbates   BBB   dysfunction   (Larochelle,   Alvarez,   &  
Prat,   2011).   Given   the   role   of   BBB   dysfunction   in   MS,   finding   compounds   that  
improve  the   integrity  of   the  BBB  or  restrict  migration  of   immune  cells   into   the  brain  
therefore  represent  important  clinical  targets.  For  example,  Natalizumab  (Tysabri),  a  
humanized   recombinant  monoclonal   antibody   that   inhibits   leukocyte  migration   into  
the  brain  has  been  shown  to  reduce  inflammation,  occurrence  of  active  lesions  and  
relapse   rates   in   relapsing-­remitting   MS   (Hutchinson,   2007).   In   addition   to   directly  
targeting   the   BBB   to   prevent   the   entry   of   inflammatory   cells   or   pathogens   during  
disease,  enabling  the  delivery  of  therapeutics  to  their  sites  of  action  within  the  brain  
is  also  critical.  Many  therapeutic  compounds  shown  to  improve  functional  outputs  in  
vitro,   often   fail   during   clinical   testing   due   to   incomplete   BBB   penetrance.   This  
highlights   that   the   bottleneck   in   drug   discovery   is   often   not   due   to   a   lack   of  
candidates  but  rather  a  lack  of  understanding  of  BBB  physiology  and  suitable  in  vitro  
and   in  vivo  tests  of  drug  permeability.  The  reasons  why  many   in  vitro  models  fail  to  
replicate  the  BBB  faithfully  in  vitro  is  1)  they  lack  fluid  flow  and  2)  they  focus  primarily  
on   replicating   the   unique   barrier   function   while   neglecting   the   dynamic   cell-­to-­cell  
communications   that   occurs   between   cells   of   the   NGVU   (Brown   et   al.,   2015).   By  
combining  microfluidics  with  3D  multi-­compartment  cell  culture,  a  number  of  BBB-­on-­
chip  devices  have  been  generated  that  more  closely  mimic  the  NGVU  environment  
(Achyuta  et  al.,  2013;;  Brown  et  al.,  2015).    
In  a  study  by  Achyuta  et  al.,  a  multi-­layered  device  was  developed  in  which  the  top  
layer  was  populated  by  endothelial  cells  to  mimic  the  vasculature,  while  a  separate  
neural   compartment   containing   neurons,   astrocytes   and   microglia   sat   below  
separated  by  a  porous  membrane  barrier.  This  layered  set-­up  enabled  the  perfusion  
of  fluid  or  pharmacological  agents  to  be  controlled  separately  to  each  compartment  
(Achyuta  et  al.,  2013).  Using  this  system,  they  were  able  to  show  that  application  of  
an  inflammatory  stimulus  (TNF-­α)  to  the  vascular  side  of  the  device  led  to  increased  
hyperpermeability   of   the   endothelial   barrier   along   with   increased   numbers   of  
microglia  and  astrocytes  displaying  activated  phenotypes  as  would  be  expected  from  
in  vivo  data  (Achyuta  et  al.,  2013).  This  data  indicates  that  models  like  this  one  may  
be   useful   for   studying   the   influence   of   neuro-­inflammation   in   disease.   However,  
limitations  of  this  assay  include  the  use  of  rodent  tissue  rather  than  human,  a  lack  of  
pericytes   that  would   normally   surround  endothelial   cells   and  a   lack   of   fluid   flow   to  
mimic  shear  stress.  An  optimised  model  was  recently  reported  that  utilised  human-­
derived   cells   to   create   separate   neural   and   vascular   chambers,   which   included  
cultured  pericytes   (Brown  et   al.,   2015).   Importantly,   adjustable   flow  channels  were  
used  to  perfuse  fluid  across  endothelial  cells  to  re-­create  the  effect  of  shear  stress  in  
vitro.  This  resulted  in  a  model  system  that  mimicked  many  of  the  parameters  of  the  
BBB  in  vivo  including  expression  of  tight  junction  proteins,  flow-­orientated  endothelial  
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cell  polarity  and   functional  passive  and  active   transport  mechanisms   (Brown  et  al.,  
2015).  The  models  discussed  here  could  serve  two  important  functions.  Firstly,  they  
could  be  used   to   study   the  physiology  of   the  BBB  under  normal   conditions  and   in  
CNS   disorders   where   permeability   is   compromised,   and   secondly,   they   could   be  
applied   to   the  process  of   drug  development   as  useful   assays  of   drug  permeability  
and  toxicity.  
While  fabrication  of  these  devices  requires  specialised  equipment  and  expertise  not  
available   in   most   laboratories,   companies   are   now   developing   cost-­effective  
microfluidic  platforms  that  are  compatible  with  multi-­well  plate  formats  for  cell  culture  
and  high-­content  screening   (Tsui,  Lee,  Pun,  Kim,  &  Kim,  2013;;  Volpatti  &  Yetisen,  
2014).   In   addition,   recent   improvement   in   3D   cell   culture   is   reducing   tissue  
heterogeneity   and   increasing   production   efficiency   enabling   the   development   of  
standardised   platforms   for   high-­throughput   compound   screening,   drug   testing   and  
disease  modelling  (Qian  et  al.,  2016).  
  
Whole-­organism  chemical  screening  
Although   organ-­on-­chip   technology   has   been   heralded   as   the   replacement   to  
traditional   in   vivo   models,   whole   animal   testing   is   still   the   gold   standard   for   drug  
discovery  and  development.  Generally,   this  has   involved  the  use  of  rodent  models,  
but   the   low-­throughput  and  high  cost   in   terms  of  animals,   time  and  money  present  
significant   drawbacks   to   their   continued   use.   Small   model   organisms   such   as   the  
zebrafish   Danio   Rerio,   nematode   Caenorhabditis   elegans,   fruit   fly   Drosophila  
melanogaster  and  African  clawed  frog  Xenopus  are  providing  attractive  alternatives  
for  drug  screening  due  to  their  genetic  amenability,  low  maintenance  costs  and  fast  
development  times.  The  advantages  of  such  models  for  screening  was  realised  early  
on  and  led  to  a  number  of  influential  large-­scale  genetic  screens  being  carried  out  in  
c.   elegans,   Drosophila   and   zebrafish   (Brenner,   1974;;   Nusslein-­Volhard,   2012;;  
Nusslein-­Volhard  &  Wieschaus,  1980).  More   recently   these  model  organisms  have  
also  been  employed  for  chemical  screening  approaches  (Strange,  2016).  Unlike  flies  
and   worms,   which   do   not   have   myelinated   axons,   the   vertebrate   zebrafish   and  
Xenopus  models  share  a  number  of  attributes  that  make  them  particularly  suited  for  
the  study  of  myelination   in  vivo  (Bin  &  Lyons,  2016).  To  date,  zebrafish  have  been  
employed   for  both  chemical  screens  and  studies  of  myelination   to  a  greater  extent  
than  Xenopus.    
Zebrafish  
Over  the  last  couple  of  decades,  zebrafish  have  emerged  as  a  powerful  and  versatile  
model  organism   for   the  study  of  developmental  biology   in  vivo  and,  more   recently,  
for   small-­molecule   drug   discovery.   Their   rapid   external   development   and  
transparency   during   larval   stages   allows   non-­invasive   live   imaging   of   glial  
development  and  myelination  (Czopka,  Ffrench-­Constant,  &  Lyons,  2013;;  Nawaz  et  
al.,  2015;;  Snaidero  et  al.,  2014).  Furthermore,  discovery  screens  and  targeted  gene  
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analyses   have   revealed   novel   mechanisms   of   myelination   and   conservation   with  
mammals   (e.g.   (Kazakova   et   al.,   2006;;   Lyons,   Naylor,   Scholze,   &   Talbot,   2009;;  
Monk   et   al.,   2009;;  H.  C.   Park,  Mehta,   Richardson,   &   Appel,   2002;;   Pogoda   et   al.,  
2006;;  Snyder,  Kearns,  &  Appel,   2012)).   It   could  be  argued   that   zebrafish  are  also  
uniquely  suited  for  high-­throughput  chemical  screening.  Zebrafish   larvae  are  only  a  
few   millimetres   in   length   making   them   particularly   amenable   to   treatment   within  
multi-­well  plates  and  the  ease  with  which  large  numbers  of  larvae  can  be  generated  
(a   single   pair   mating   can   produce   several   hundred   offspring)   provides   a   fast   and  
expandable   source   of   embryos.   A   key   advantage   of   using   zebrafish   for   chemical  
screening   is   their   ability   to   absorb   small   molecules   directly   from   the   surrounding  
media  making  delivery  of  compounds  relatively  straightforward  and  flexible  in  terms  
of   treatment   dosage   or   timing.   In   this   way,   phenotypic   changes   in   response   to  
chemical   treatments  can  be  quickly  and  easily  screened   in   the  context  of  a  whole,  
developing  animal.  Additionally,  this  quality  endows  zebrafish  with  a  built-­in  means  to  
assess   drug   specificity,   efficacy   and   toxicity,   parameters   which   are   often   hard   or  
impossible   to   measure   in   cell-­based   assays   and   are   often   the   reason   why  
compounds  fail  during  in  vivo  testing.  
Chemical  screens  in  zebrafish  to  identify  therapeutics  for  MS  
Since  the  first  published  zebrafish  chemical  screen  in  2000,  there  have  been  over  65  
small-­molecule   screens   using   zebrafish   reported   in   the   literature   (R.   T.   Peterson,  
Link,  Dowling,  &  Schreiber,  2000;;  Rennekamp  &  Peterson,  2015).  During  this  period,  
advances   in   phenotypic   characterisation,   data   collection   and   analyses   have   led   to  
the   identification   of   a   number   of   potential   therapeutic   compounds,   with   a   handful  
currently   under   investigation   in   clinical   trials   (Rennekamp   &   Peterson,   2015).   The  
success   of   zebrafish   as   a   model   organism   for   drug   discovery   can   in   part   be  
attributed  to   their  high  degree  of  homology  to  humans.  Following  completion  of   the  
zebrafish  genome  sequencing  project   in  2013,  over  70%  of  human  genes  are  now  
believed   to  have  at   least  one  obvious  orthologue   in   zebrafish   (Howe  et  al.,   2013).  
This  high  degree  of  conservation  is  also  evident  in  their  pharmacology  with  an  ever-­
increasing   number   of   compounds   tested   in   humans   having   similar   effects   in  
zebrafish   (Milan,   Peterson,   Ruskin,   Peterson,   &   MacRae,   2003;;   Rennekamp   &  
Peterson,   2015).   These   similarities   have   made   the   zebrafish   a   popular   model  
organism  in  which  to  study  the  processes  of  glial  cell  development  and  function.    
Despite   the   clear   advantages   to   using   zebrafish   to   study   glial   development   and  
myelination,   few   chemical   screens   have   been   published   in   this   area.   In   2010,  
Buckley  et  al,.   published  a  drug   reprofiling  chemical   screen   in   zebrafish   to   identify  
compounds  with  potential  pro-­myelinating  properties  (Buckley  et  al.,  2010).  Using  the  
Tg(Olig2:GFP)   transgenic   line   to   identify   alterations   in   oligodendrocyte   lineage  
migration,   proliferation   and   differentiation,   treatment   with   a   library   of   over   1000  
compounds  identified  ~2%  of  compounds  that  altered  oligodendrocyte  number  in  the  
fish   (Buckley   et   al.,   2010).  Secondary   screening   for   alterations   in  myelination  was  
carried   out   using   real-­time   PCR   for   myelin   basic   protein,   which   identified   three  
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compounds   with   specific   effects,   including   a   src   family   kinase   inhibitor   known   to  
affect   myelination   in   mammals   (Osterhout,   Wolven,   Wolf,   Resh,   &   Chao,   1999).  
Taking  a  complementary  strategy  to  find  therapeutic  compounds  for  the  inflammatory  
aspects  of  MS,  Cusick  et   al.,   developed  a   screen   to   identify   suppressors  of  T   cell  
activation,  a  central   feature   in   the   immunopathogenesis  of  MS.  Using  a   transgenic  
line  to  label  T  cells,  Lenaldekar  was  identified  as  a  novel  inhibitor  of  activated  T  cell  
proliferation  (Cusick,  Libbey,  Trede,  Eckels,  &  Fujinami,  2012).  In  addition,  treatment  
with   Lenaldekar   in   an   experimental   autoimmune   encephalomyelitis   (EAE)   rodent  
model  of  MS   inhibited  relapse  severity,  highlighting  conservation   in   function  across  
species   (Cusick   et   al.,   2012).   In   a   similar   vein,   Vibsanin   B,   a   novel   macrocyclic  
diterpenoid  was   identified   in  a  zebrafish  chemical  screen   for   inhibitors  of   leukocyte  
migration   (Ye   et   al.,   2015).   Acting   preferentially   through   heat   shock   protein  
(HSP)90β,   Vibsanin   B   was   shown   to   ameliorate   CNS   inflammation   and  
demyelination  in  EAE  mice  through  inhibiting  leukocyte  infiltration  into  the  CNS  (Ye  
et  al.,  2015).    
The  availability  of   new   reporters   that  allow  assessment  of  myelinating  cell   number  
and  extent  of  myelination  (Almeida  et  al.,  2011)  directly   in  vivo  will  allow  screens  to  
be  carried  out  with  a  greater  focus  on  myelination  per  se.  In  addition,  the  variety  of  
reporter   lines   labelling   different   populations   of   cells,   such   as   neurons   (Sato,  
Takahoko,   &   Okamoto,   2006),   Schwann   cells   (Gilmour,   Maischein,   &   Nusslein-­
Volhard,   2002),   microglia/macrophages   (Ellett,   Pase,   Hayman,   Andrianopoulos,   &  
Lieschke,  2011;;  Peri  &  Nusslein-­Volhard,  2008;;  Sieger  &  Peri,  2013)  and  cells  of  the  
vasculature  (Jin  et  al.,  2007)  expands  the  type  and  nature  of  chemical  screens  that  
can  be  carried  out   in  zebrafish.  Furthermore,   the  availability  of  zebrafish  models  of  
human  disease  generated  by  gene  targeting  or  identification  through  gene  discovery  
allows   for   chemical   rescue   screens   and   studies   to   be   carried   out   that   modify  
disease-­related   phenotypes.   For   example,   it   was   recently   shown   that   clemastine  
treatment   could   rescue   hypomyelination   in   mct8   mutant   zebrafish   (Zada,   Tovin,  
Lerer-­Goldshtein,   &   Appelbaum,   2016).   In   addition,   as   with   humans   and   rodents,  
zebrafish   possess   a   BBB   which   begins   to   form   from   just   3dpf   in   the   larvae   (Xie,  
Farage,   Sugimoto,   &   Anand-­Apte,   2010),   allowing   one   to   study   the   breakdown   of  
barrier  permeability,   central   to   conditions  such  as  MS,  or   to   screen   for   therapeutic  
compounds   capable   of   crossing   the   BBB   in   vivo.   Given   the   promise   of   using  
zebrafish   for   chemical   screening,   significant   effort   is   currently   being   invested   in  
automating  various  aspects  of  the  screening  pipeline  from  mass  embryo  production  
systems,   automated   handling   and   positioning   of   embryos   (T.-­Y.   Chang,   Pardo-­
Martin,   Allalou,   Wählby,   &   Yanik,   2012;;   Pardo-­Martin   et   al.,   2013;;   2010;;   Pulak,  
2016),  high-­speed  imaging,  and  automated  analyses  (G.  Wang  et  al.,  2015;;  White  et  
al.,  2016).  Advances  in  these  areas  will  help  ensure  that  zebrafish  also  contribute  to  
identifying  and  developing  novel  and  disease-­relevant  therapeutics.  
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Conclusions  
Glial   cells   are   now   known   to   regulate  many   aspects   of   nervous   system   formation,  
function  and  health.  Their  disruption  is  prevalent  in  arguably  all  diseases  of  the  CNS,  
whether   representing   primary   causation   or   secondary   consequence   of   disease.   In  
any  case,  manipulation  of  glia  may  represent   therapeutic  options   for  many  disease  
states.  Here  we  have  focussed  on  the  working  model  that  promoting  the  endogenous  
capacity  of  our  CNS  to  regenerate  myelin  may  be  an   important  means  by  which  to  
treat   MS.   MS   is   a   complex   disease,   and   it   is   entirely   likely   that   its   life-­long  
management   will   require   multiple   integrated   strategies.   Targeting   the   adaptive  
immune  system  will  remain  core  to  the  treatment  of  the  early  stages  of  disease  and  
possibly   also   later   stages.   However,   we   expect   that   this   will   be   augmented   by  
interventions   that   promote   remyelination.   The   recent   success   of   hypothesis   driven  
studies   and   phenotypic   screening   studies   indicate   that   medicines   to   enhance  
oligodendrocyte  differentiation  may  soon  be  on   the  horizon.   It   is  possible   that   they  
will  be  followed  by  interventions  that  target  other  cell  types  and  cell-­cell  interactions  
to  allow  or  enhance  remyelination.  Drug  development  focussed  studies  surrounding  
the   roles   of   additional   cell   types   and   their   interactions   currently   lag   behind   those  
aiming   to   promote   oligodendrocyte   differentiation,   but   are   feasible.   Here   we   also  
aimed  to  provide  an  overview  of  at  least  some  technologies  that  could  be  employed  
to  study  cells  of  the  nervous  system  and  their  interactions  with  therapeutic  agents  in  
more  detail  and  at  greater  scale.  Such  approaches  are  obviously  in  no  way  restricted  
to   analyses   of   remyelination   and  we   anticipate   that   they  will   play   key   roles   in   the  
continued  establishment  of  glial  cells  as  generally  relevant  targets  for  the  treatment  
of  disease.    
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Lingo  1   Anti-­lingo1  antibody   Blocks  signals  inhibitory  to  differentiation   Phase  II  trial  completed  
Nogo-­A   Anti-­Nogo-­A  antibody   Blocks  signals  inhibitory  to  differentiation   Second  Phase  I  trial  on-­going  
Unknown   rHIgM22  antibody     Unknown   Phase  I  trial  on-­going  
RxR    
Bexarotene  (pan  RXR  
agonist)  
Selective  agonists  in  
development  
Promotes  oligodendrocyte  
differentiation   Trial  in  recruitment  phase  
Wnt  pathway   Tankyrase  Inhibitor  (XAV939)  
Blocking  signals  inhibitory  to  
differentiation  
Not  yet  pursued-­affects  many  cell  
types  
Mitochondrial  permeability  
transition  pore   Olesoxime     Unknown  
Phase  Ib  trial  completed,  well  
tolerated  
Phosphodiesterase-­4     Inhibitor  (Rolipram)       Unknown   Poorly  tolerated  in  previous  trials-­  affects  many  cell  types  
Gpr17     Pranlukast  (non-­selective  antagonist)  
Promotes  oligodendrocyte  




BQ3080  (EDNRB  agonist)  
Promotes  oligodendrocyte  
differentiation  and  myelination     Not  yet  pursued  




























Not  yet  pursued  
Clemastine  (Antagonist)   Phase  II  trial  completed  
Solifenacin  (Antagonist)   Not  yet  pursued  
κ-­opioid  receptor   (±)-­U-­50488  (KOR  agonist)  
Promotes  oligodendrocyte  
differentiation  and  survival   Not  yet  pursued  
Glucocorticoid  receptor   Clobetasol  (Agonist)   Promotes  oligodendrocyte  differentiation   Not  yet  pursued  
Unknown  acting  on  MAPK   Miconazole  (Unknown)   Promotes  oligodendrocyte  differentiation  and  myelination   Not  yet  pursued  
Table	  1.	  Summary	  of	  candidates	  and	  compounds	  that	  promote	  remyelination	  in	  vivo	  that	  have	  therapeutic	  potential	  




et  al.  (2013)  
Mei  et  al.  
(2014)  
Mei  et  al.  
(2016)  
Najm  et  al.  
(2015)  
Peppard  
et  al.  (2015)  




et  al.  (2016)  
Library   In  house,  
LOPAC  and  
NINDS  












Compounds   3000   ~100000   1000   ~250   727   ~73000   1200   727  
Concentration   3,  30  or  
60µM  
1.5µM   1µM   1µM   5µM   3µM   1,  10  &  
25µM  
2  of  10,  2,  0.4  
or  0.08µM  
Organism   Mouse   Rat   Rat   Rat   Mouse   Rat   Mouse   Rat  
Cell  Type   Oli-­neu  cell  
line  
Primary  OPCs   Primary  
OPCs  
Primary  OPCs   EpiSC-­  derived  
OPCs  











Relative  %MBP  vs  PDGFRA  
+ve  rings  surrounding  
micropillars  
Process  Length  








Hits   10  in  3  
classes  
54  in  19  
classes  










Not  specified   Not  specified   Not  specified   Orthogonal  
assay,  EC50,  ex  
vivo  slice  
cultures  




up  in  vivo  
N/A   Benztropine   Clemastine   (±)-­U-­50488   Clobetasol  and  
Miconazole  
N/A   N/A   N/A  
In  vivo  
validation  










None   None   None  
	  
Table	  2.	  Summary	  of	  phenotypic	  screens	  that	  identified	  compounds	  promoting	  oligodendrocyte	  differentiation	  
	  
Box  1  -­  In  vivo  models  of  demyelination:  
There  are  several  commonly  used  animal  models  of  demyelination,  each  with  their  own  advantages  and  disadvantages.  
1.  Experimental  autoimmune  encephalomyelitis  (EAE):  
•   Animal  is  sensitised  to  spinal  cord  homogenate,  myelin  protein  or  peptide  fragment  
•   T-­Cell  mediated  demyelination  
•   Blood  brain  barrier  compromised  
•   Many  variants  of  model  exist  
•   Demyelination  is  somewhat  variable  in  localisation  and  extent  and  occurs  concomitantly  with  axonal  injury  
  
2.  Focal  gliotoxin-­induced  demyelination:  
•   Chemical  induced  demyelination  
•   Several  treatments  used,  including:  ethidium  bromide,  calcium  ionophores,  anti-­galactocerebroside  antibodies  and,  most  commonly,  
lysolecithin  (lysophosphatidylcholine)  
•   High  degree  of  spatial  and  temporal  control  of  demyelination  
•   No  T-­cell  mediated  inflammation  
•   Single  episode  of  demyelination  allows  study  of  timing  of  regenerative  remyelination  
  
3.  Systemic  demyelination  using  cuprizone:  
•   Global  treatment  with  copper  chelating  agent  
•   Reversible  following  treatment  cessation  
•   No  T-­cell  mediated  inflammation  
•   Demyelination  largely  studied  in  the  corpus  callosum  
•   Co-­treatment  with  rapamycin  gives  more  extensive  and  prolonged  demyelination  
	  
	  
